CURE AIDS NOW

CURE AIDS NOW IS A NON PROFIT PLAN TO ERADICATE HIV / AIDS WITH AN INTERNET TECHNOLOGY SOLUTION PARTNER AND A USPTO UTILITY PATENT PARTNER APPROVED BY THE EPA AND FDA

[US Patent & Trademark Office, Patent Full Text and Image Database]
[Home] [Boolean Search] [Manual Search] [Number Search] [Help]
[Bottom]
[
View Shopping Cart] [Add to Shopping Cart]
[Image]
( 1 of 1 )
United States Patent 7,135,195
Holladay , et al. November 14, 2006
Treatment of humans with colloidal silver composition

CURE AIDS NOW PATENT # 7,135,195

Abstract
We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5 40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described.

Inventors: Holladay; Robert J. (Logan, UT), Christensen; Herbert (Alpine, UT), Moeller; William D. (Alpine, UT)
Assignee: American Silver, LLC (Alpine, UT)
Family ID: 34317391
Appl. No.: 10/641,938
Filed: August 15, 2003
Prior Publication Data
Document Identifier Publication Date
US 20050061678 A1 Mar 24, 2005
Related U.S. Patent Documents
Application Number Filing Date Patent Number Issue Date
09946834 Sep 4, 2001 6743348
09323310 Jun 1, 1999 6214299
60475657 Jun 3, 2003
Current U.S. Class: 424/618; 424/405; 424/489; 424/490; 424/616; 514/849; 514/858; 514/894; 514/895; 514/924; 514/931; 514/932; 514/934; 514/951
Current CPC Class: A61K 9/0014 (20130101); A61K 9/0043 (20130101); A61K 9/0046 (20130101); A61K 9/0095 (20130101); A61K 33/38 (20130101); A61K 33/40 (20130101); A61K 45/06 (20130101); A61K 47/10 (20130101); A61K 47/32 (20130101); A61L 2/16 (20130101); A61L 2/238 (20130101); B01F 7/22 (20130101); B01F 13/0001 (20130101); B01F 13/0003 (20130101); B01J 13/0043 (20130101); B01J 19/087 (20130101); B01J 19/18 (20130101); C02F 1/4606 (20130101); A61K 9/0034 (20130101); A61K 33/38 (20130101); A61K 33/40 (20130101); Y10S 514/895 (20130101); A61L 2/186 (20130101); B01J 2219/082 (20130101); B01J 2219/0835 (20130101); B01J 2219/0841 (20130101); B01J 2219/089 (20130101); C02F 2303/04 (20130101); Y10S 514/932 (20130101); Y10S 514/858 (20130101); Y10S 514/934 (20130101); Y10S 514/951 (20130101); Y10S 514/931 (20130101); Y10S 514/894 (20130101); Y10S 514/849 (20130101); Y10S 514/924 (20130101); A61K 2300/00 (20130101); A61K 2300/00 (20130101)
Current International Class: A61K 33/38 (20060101); A01N 25/12 (20060101); A01N 25/26 (20060101); A01N 59/00 (20060101); A01N 59/16 (20060101); A61K 33/40 (20060101); A61K 9/10 (20060101); A61K 9/14 (20060101); A61P 11/00 (20060101); A61P 13/00 (20060101); A61P 15/00 (20060101); A61P 15/02 (20060101); A61P 17/00 (20060101); A61P 31/00 (20060101); A61P 31/02 (20060101); A61P 31/04 (20060101); A61P 31/10 (20060101)
Field of Search: ;424/618,405,489,490,616 ;514/849,858,894,895,924,931,932,934,951
References Cited [Referenced By]
U.S. Patent Documents
6214299 April 2001 Holladay et al.
6743348 June 2004 Holladay et al.
6890953 May 2005 Arata
6939568 September 2005 Burrell et al.
2002/0051823 May 2002 Yan et al.
2003/0185889 October 2003 Yan et al.
Primary Examiner: Pak; John
Attorney, Agent or Firm: Liner, Yankelevitz, Sunshine & Regenstreif LLP
Parent Case Text

The present application is a continuation-in-part of application Ser. No. 09/946,834, filed Sep. 4, 2001, now U.S Pat. 6,743,348 which is a continuation of application Ser. No. 09/323,310, filed Jun. 1, 1999, now U.S. Pat. No. 6,214,299. The present application claims priority to provisional application 60/475,657, filed Jun. 3, 2003, and incorporated by reference herein.
Claims

We claim:

1. A composition of silver in water comprising a total concentration of silver of between about 5 and 40 parts per million, said silver in the form of colloidal silver particles having an interior of elemental silver and a surface of silver oxide, wherein a majority of the colloidal silver particles have a maximum diameter less than 0.015 micrometers, wherein a majority of the colloidal silver particles have a minimum diameter greater than 0.005 micrometers, and wherein the composition exibits antimicrobial properties.

2. The composition according to claim 1, wherein at least 75% of the colloidal particles have diameters between 0.005 micrometers and 0.015 micrometers.

3. The composition according to claim 2, wherein at least 90% of the colloidal particles have diameters between 0.005 micrometers and 0.015 micrometers.

4. The composition according to claim 3, wherein at least 95% of the colloidal particles have diameters between 0.005 micrometers and 0.015 micrometers.

5. The composition according to claim 1, wherein the colloidal particles have an average diameter of about 0.0106 micrometers.

6. The composition according to claim 1 further comprising hydrogen peroxide.

7. The composition according to claim 6, wherein the hydrogen peroxide concentration is between about 1% wght/v and about 3.0% wght/v.

8. The composition according to claim 1, wherein the composition exhibits antimicrobial properties against microbes selected from the group consisting of Bacillus anthracis, Bacillus subtilis, Candida albicans, Mycobacteria bovis, Mycobacteria tuberculosis, Pseudomonas aeruginosa, Salmonella choleraesius, Staphylococcus aureus, Trichomonas vaginalis, and Yersinia pestis.

9. The composition according to claim 8, wherein Staphylococcus aureus is a methicillin-resistant strain.

10. The composition according to claim 1, wherein the composition exhibits antimicrobial properties against microbes associated with diseases selected from the group consisting of malaria, fungal infections of the skin, bacterial infections of the skin, vaginal infections, urinary tract infections, tonsillitis, pelvic inflammatory disease, pharyngitis, gonorrhea, conjunctivitis, otitis, respiratory tract infections, and nasal infections.

11. The composition according to claim 1, wherein the antimicrobial properties are antiviral properties.

12. The composition according to claim 11, wherein the antiviral properties are exhibited against a virus selected from the group consisting of human immunodeficiency virus and hepatitis B virus.

13. The composition according to claim 11, wherein the antiviral properties include inhibition of viral DNA polymerase.

14. The composition according to claim 11, wherein the antiviral properties include inhibition of viral reverse transcriptase.
Description

AREA OF THE ART

The present invention generally relates to colloidal silver, and more particularly to a composition of colloidal silver and a method for using said composition as an agent against organisms harmful to the health of humans.

DESCRIPTION OF THE PRIOR ART

It is well known that certain preparations of silver have germicidal properties. Silver was employed as a germicide and an antibiotic before modern antibiotics were developed. In previous centuries, users would shave silver particles into their drinking water, or submerge whole silver pieces in the drinking water, for the purpose of ingesting the silver by drinking the water. It seems likely that the practice of eating with silver utensils (i.e., silverware) resulted from a belief in the healthful properties of silver.

There may be many reasons why administering silver suspended in solution would enhance an individual’s health. It is possible that such a solution operates to inhibit the growth of bacteria, viruses, and other unwanted organisms, as well as eradicating such existing bacteria, viruses, and other organisms. It is also possible that a solution of silver can have an anti-inflammatory effect, sufficient to reduce symptoms of asthma.

The present invention describes the use of a silver composition in water to treat certain human ailments. An embodiment of the invention is a silver composition comprising small particles of silver which comprise an interior of metallic silver and an exterior of ionic silver which particles are suspended in water. A preferred embodiment of the invention is a silver composition comprising particles of silver wherein more than 50% of the number of particles are less than 0.015 micrometers in size and the particles are colloidally suspended in water.

SUMMARY OF THE INVENTION

The present invention is generally directed to the use of silver, at a level of 5 to 40 ppm in water, to kill or to disable microorganisms which are hazardous to human beings. The present invention specifically is directed to compositions comprising silver particles, said particles comprising an interior of elemental silver and an exterior of ionic silver oxide, and water, wherein the silver particles are placed in colloidal suspension in the water at a level of 5 40 ppm total silver. An embodiment of the present invention comprises silver particles in water, at a concentration of 5 40 ppm, wherein more than 50% of the silver particles have a maximum dimension less than 0.015 micrometers. The composition of silver in water of this invention is an effective antimicrobial agent. This invention is directed to silver compositions, of 5 40 ppm silver in water, which are effective antimicrobial agents, and to methods of using said silver compositions as antimicrobial agents.

A preferred embodiment of the present invention is directed to compositions of silver in water made using a modification of the device and methods described in U.S. Pat. No. 6,214,299, which is a parent of the instant application and is incorporated herein by reference.

The device and process of Pat. No. 6,214,299 have been modified and improved to provide the silver composition of the present invention. Essentially, the eight-silver/one common electrode device as disclosed in the patent has been modified and scaled to fit a 75-gallon water chamber. To start the process approximately 70 gallons of high purity water are placed in the chamber. To this is added approximately five gallons of silver composition produced in a prior production run. This is necessary because the high purity water is insufficiently conductive for the process to occur properly. The water chamber is equipped with an air input that allows a stream of air bubbles to be streamed through the liquid during the processing. It has been discovered that this approach gives improved mixing as compared to the impeller mixer described in the patent.

The electrode device is operated at approximately ten thousand volts alternating current (with each silver electrode having an individual voltage supply) as described in the patent. It has been found that voltages significantly lower than this produce a composition with larger particles not having the optimal properties described herein. Voltages significantly higher tend to produce a solution with significant ionic silver dissolved therein. The present composition comprises in excess of 97% metallic silver with essentially no free ionic silver in solution.

The silver concentration is determined according to the methods explained below. Essentially, the device is operated continuously and samples are analyzed until the desired silver concentration is attained. The 10 ppm composition requires approximately one and one half days of operation. The 22 ppm solution requires approximately three days, and the 32 ppm composition requires approximately six days. The rate of the process appears to slow as the higher concentrations are attained. Higher concentrations take a prohibitively long time with the ultimate highest concentration being about 50 ppm, at least within the current parameters.

The compositions all have the size characteristics described below and unlike conventional silver compositions are completely colorless and stable to light and temperature changes without use of any additives. The compositions are unreactive towards added hydrogen peroxide.

Hydrogen peroxide, a know disinfecting agent, has been found to have a synergistic interaction with the inventive silver composition. Hydrogen peroxide is available in concentration of 30% wght/v (% weight per volume or weight percent) or higher. Although the higher concentrations are usable, the preferred concentrations are in the range of 1 to 5% wght/v.

A preferred embodiment of the present invention is directed to compositions comprising 5 to 40 ppm silver, said silver being primarily elemental silver, 1 to 3 wght % hydrogen peroxide, and water. A preferred embodiment of the present invention is the use, and method of use, of compositions comprising 10 to 40 ppm silver and 1 to 3 wght % hydrogen peroxide in water as antimicrobial agents.

DETAILED DESCRIPTION OF THE INVENTION

The following description is provided to enable any person skilled in the art to make and use the invention and sets forth the best modes contemplated by the inventor of carrying out his invention. Various modifications, however, will remain readily apparent to those skilled in the art, since the general principles of the present invention have been defined herein specifically to provide an improved colloidal silver product with significant abilities to kill human pathogens both in vivo and in vitro.

Generally, the present invention represents a novel approach to killing or disabling microorganisms which are hazardous to human beings by the use of silver particles in water, at a concentration of 5 to 40 ppm silver. Depending upon the application, the silver composition may be used internally or externally. Depending on the application, the silver composition may also contain hydrogen peroxide.

PREFERRED EMBODIMENTS

Non-limiting preferred embodiments are presented in the following:

A composition comprising silver particles, colloidally suspended in water, wherein the total content of silver is between 5 and 40 ppm, which composition kills or disables microorganisms which are hazardous to the human body.

A composition comprising silver particles, colloidally suspended in water, wherein the total content of silver is about 10.+-.2 ppm, which composition kills or disables microorganisms which are hazardous to the human body.

A composition comprising silver particles, colloidally suspended in water, wherein the total content of silver is about 22.+-.2 ppm, which composition kills or disables microorganisms which are hazardous to the human body.

A composition comprising silver particles, colloidally suspended in water, wherein the total content of silver is about 32.+-.3 ppm, which composition kills or disables microorganisms which are hazardous to the human body.

It will be appreciated that specifying the total amount of silver in a composition of particles does not completely specify the material. As the particles comprising the composition are made smaller, a given concentration of silver will represent a larger number of particles. In addition, the total surface area for a given silver concentration will increase. Therefore, particles size and range of particle size is an important parameter for defining an effective inventive composition.

A further class of embodiments is any of the above-described compositions, wherein more than 50% of the silver particles have a maximum dimension less than 0.015 micrometers.

A further class of embodiments is any of the above-described compositions, wherein more than 75% of the silver particles have a maximum dimension less than 0.015 micrometers.

A further class of embodiments is any of the above-described compositions, wherein more than 90% of the silver particles have a maximum dimension less than 0.02 micrometers.

A further class of embodiments is any of the above-described compositions, wherein more than 75% of the silver particles have a minimum dimension greater than 0.005 micrometers.

A further class of embodiments is any of the above-described compositions, wherein more than 90% of the silver particles have a minimum dimension greater than 0.005 micrometers.

A further class of embodiments is any of the above-described compositions, wherein the silver particles comprise both silver in the

A further class of embodiments is any of the above-described compositions, wherein the silver particles comprise both silver in the zero-valent, that is, metallic, oxidation state [Ag(O)] and a coating of silver in an ionic oxidation selected from the group consisting of Ag(I), Ag(II), and Ag(III).

A further class of embodiments is any of the above-described compositions, wherein the silver particles comprise both silver in the zerovalent, that is metallic, oxidation state [Ag(O)] and a coating of silver oxide with the stoichiometry AgO.

Experimental evidence shows that AgO in the particles of the present invention is at least partially in the form of Ag.sub.4O.sub.4–that is, silver II oxide. In a molecule of this material two of the silver atoms are in the 1.sup.+ state (silver I) while the other two silver molecules are in the 3.sup.+ state (silver III). Under certain conditions these molecules can give rise to silver atoms in the 2.sup.+ (silver II) state.

A further class of embodiments is the combination of any of the above-described embodiments with hydrogen peroxide, at a level of 1 3 wgt % hydrogen peroxide in the final product.

EXAMPLES

1. Formation of Composition

Compositions of silver in water can be made according to procedures set forth in U.S. Pat. No. 6,214,299, incorporated by reference herewith.

A preferred method for producing a composition comprising silver according to this invention utilizes a electrochemical cell comprising electrodes and comprises the steps

(a) placing a silver electrode in contact with a quantity of high purity water;

(b) conveying electrical current through the silver electrode to thereby separate particles of silver from said silver electrode in a manner sufficient to cause production of suspended silver particles within the water; and

(c) agitating the water during said production of suspended silver particles to thereby disperse the silver particles into a more uniform concentration within said water such that a higher quantity of suspended silver particles can be produced per batch.

Another preferred method for producing a composition comprising silver utilizes an electrochemical cell and comprises the steps of:

(a) establishing an electrical circuit comprising a current source, and a first conductor electrically connected to said current source and a second conductor electrically connected to said current source, wherein said first conductor is disposed spaced apart from said second conductor, and wherein at least one of the conductors is made of elemental silver;

(b) closing the circuit by placing the first conductor and the second conductor in communication with a fluidic resistor;

(c) operating the current source to supply alternating current simultaneously to the first conductor and the second conductor such that voltage is increasing and decreasing within the first and second conductors in alternating tandem to thereby cause silver particles to separate from the first electrode and enter the fluidic resistor and become disposed in suspension within said fluidic resistor; and

(d) selectively adjusting the electrodes by moving them toward the fluidic resistor to compensate for decrease in electrode length due to gradual separation of silver particles therefrom to thereby prevent arcing from occurring between the electrodes and said fluidic resistor.

The analysis of the silver content in the silver compositions of this invention may be done by atomic absorption (AA), inductively coupled plasma/atomic emission (ICP/AES), or other techniques known to one of ordinary skill in the art to be sensitive to silver in the appropriate concentration range. If the particles of the silver composition are small and uniformly sized (for example, 0.01 micrometers or less), a reasonably accurate assay may be obtained by running the colloid directly by AA or ICP/AES. This is because the sample preparation for AA ionizes essentially all of the silver allowing its ready detection.

If the compositions comprise particles as large as 0.2 micrometers, it is preferred to use a digestion procedure. The digestion procedure is not necessarily ideal for silver compositions that may have been manufactured or stored in contact with halides or other anionic species that may react with finely divided silver, or combined with protein or other gelatinous material. An embodiment of the digestion procedure is as follows:

1 Take a 10 ml aliquot of a thoroughly mixed or shaken silver composition to be analyzed, and place it in a clean polycarbonate bottle or other container of suitable material (generally, the bottle) with a tight fitting lid. A size of 30 100 ml is preferred.

2 With a micropipette or dropper, add 0.1 ml of nitric acid, reagent grade to the silver composition in the bottle.

3 With the lid of the bottle tightly in place, heat the silver composition to 80.degree. C. with mild agitation for a time sufficient to dissolve the silver-dissolution is essentially instantaneous.

4 Allow the resulting mixture to cool to room temperature with the lid in place. Shake the bottle thoroughly.

5 Utilize AA, ICP/AES, or equivalent means to analyze the silver content of the silver mixture. Preferably, one will utilize a freshly prepared standard or standards, preferably prepared according the equipment manufacturer’s instructions, with appropriate dilution as needed.

6 When reporting results, one must taken into account all dilutions during preparation, including the 1% dilution caused by addition of the nitric acid.

1. Analysis of Physical/chemical Form of Silver

A. Introduction

A sample of a composition, nominally containing 22 ppm silver in water, was analyzed by time-of-flight secondary ion mass spectrometry (TOF-SIMS) in order to determine the form of silver in the composition. The conclusion is that the bulk of the silver exists as silver (O) [that is, metallic silver] and that there is a surface coating which as on average a composition of silver (II) oxide [AgO]. As mentioned above silver (II) oxide is usually a stoichiometric combination of silver (I) and silver (III).

B. Experimental Procedure

A few drops of the 22 ppm inventive silver composition were evaporated to dryness on a silicon substrate at ambient temperature. The residue was analyzed by TOF-SIMS, and is denoted as the sample. A reference silver (II) oxide (AgO) material was analyzed by placing a few particles of the reference powder as received from the vendor on a silicon substrate, and is denoted as the reference.

The Time-of-Flight Secondary Ion Mass Spectrometry technique (TOF-SIMS) is based on the principle of bombarding a solid sample with a pulsed, finely focused beam of primary ions, and then analyzing the secondary ions produced from the surface of the sample via a time-of-flight mass spectrograph. This analytical technique is surface sensitive, deriving its information from a layer that extends to approximately 20 to 40 .ANG. (one Angstrom=1.times.10-4 micrometers) below the surface. The TOF-SIMS technique is normally used as a survey tool to identify the composition of unknown samples. It is capable of quantification if the appropriate microanalytical standards are available for calibration. This analysis was carried out using standard high mass-resolution conditions.

C. Results

Negative ion mass were obtained for the Ag(II)O reference material and the product sample, respectively. The mass spectral region for both spectra showed the presence of AgO- species. The data suggest that silver (II) is the average oxidation state of the silver present on the surface of the sample particles. The silver oxide (AgO) signals exhibit significantly higher intensity in the reference sample compared to the product sample which is probably because metallic silver is dominant in the sample. It will be appreciated that as the average particle size in the sample is decreased the ratio of silver to silver oxide will also decrease as more silver oxide will be present.

2. Size Analysis

It is likely that the unusual effectiveness of the silver preparations described herein is due to the relationship between the surface properties/inner properties (i.e., oxide/metal) of the particles and the size distribution of the particles. The smaller the average particle size, the greater the surface area and the greater the contribution of the particular surface chemistry. However, if the particles are excessively small there can be a loss of stability and/or other interactions that negatively affect the product. The silver compositions of the instant invention are remarkable because they are stable in essentially pure water without surf actants, etc. Also, the materials are essentially colorless while other colloidal silver preparations (particularly with larger particle sizes) usually show colors. These properties are a result of the exact manufacturing conditions as discussed above.

Digital analysis of the composition showed that there is an average particle diameter of 0.0106 micrometers with a range of 0.005 micrometer to 0.0851 micrometers. However, size distribution analysis shows that more than 95% of the particles were between about 0.005 micrometers and about 0.015 micrometers in diameter.

3. Evidence of Efficacy of 22 ppm Silver Composition Against Bacillus Subtilis

A. Purpose of Example

The purpose of this example is to demonstrate the antimicrobial activity of the silver-based composition of the present invention on bacterial endospores from the test organism Bacillus subtilis. This was accomplished by performing a standard kill-time assay using a suspension of B. subtilis endospores. Normally, bacterial endospores are resistant to killing.

B. Material and Methods

Test Organism. A test suspension containing endospores from Bacillus subtilis (ATTC #19659) was prepared from a culture grown on nutrient agar, to which additional sporulation enhancement ingredients were added. Plates were harvested with sterile water and endospores were purified by repeated centrifugations and resuspensions in water. The final wash was in 70% ethanol for 30 min, to ensure the destruction of all vegetative bacteria. The spores were resuspended in water containing 0.1% Tween 80 (brand of polysorbate surfactant) to prevent clumping.

Neutralizer. The Neutralizer mixture consisted of 12.7% Tween.RTM. 80 (brand of polysorbate), 6.0% Tamol.RTM. SN (brand of sodium salt of naphthalene-formaldehyde condensate), 1.7% lecithin, 1% Peptone, and 0.1% Cystine. This solution was intended to neutralize any chemicals so they would not affect subsequent growth of the bacteria.

Kill-Time Procedure:

a) A 9.9 ml aliquot of the disinfectant (inventive 22 ppm silver composition, in water) was placed in a sterile 20 mm.times.150 mm tube. The tube was equilibrated in a 20.degree. C. water bath.

b) A 9.9 ml aliquot of the disinfectant (inventive 22 ppm silver composition, in water) was placed in a sterile 20 mm.times.150 mm tube. The tube was equilibrated in a 20.degree. C. water bath.

c) At 30 min. 1 hr, and 4 hr, one ml of organism/disinfectant suspension was removed to a tube containing nine ml of Neutralizer. The tube was mixed thoroughly.

d) After two min, the neutralized suspension was serially diluted 1:10, in physiological saline solution (PSS).

e) The number of viable organisms in selected dilution tubes was assayed by membrane filtration. One ml aliquots were plated in duplicate. The membranes were washed with about 100 ml of sterile PSS and removed to Nutrient Agar plates. The plates were incubated at 37.degree. C. for 20 hr.

f) The number of colonies on each filter was counted and log reductions were computed.

Controls:

a) Titers of the test suspensions were computed by performing membrane filtration assays of selected 1:10 dilutions of the test suspensions in PSS.

b) A neutralizer control was performed by inoculating a mixture of 9 ml neutralizer and 1 ml of disinfectant with 100 .mu.l of a dilution of the titer containing 100 cfu. This produced about 10 cfu/ml in the tube, which was allowed to stand for 20 minutes prior to assay by membrane filtration using duplicate 1 ml samples.

C. Results

Bacillus subtilis Titer:

TABLE-US-00001 Dilution: 1:1 .times. 10.sup.6 1:1 .times. 10.sup.7 1:1 .times. 10.sup.8 Number of colonies: TNTC 75 7 TNTC 58 8 TNTC = too numerous to count

TABLE-US-00002 Dilution of B. subtilus spore/disinfectant suspension: Time 1:1 .times. 10.sup.1 1:1 .times. 10.sup.2 1:1 .times. 10.sup.3 1:1 .times. 10.sup.4 1:1 .times. 10.sup.5 1:1 .times. 10.sup.6 30 min — – TNTC TNTC 57 10 — – TNTC TNTC 51 7 1 hr — – TNTC TNTC 28 3 — – TNTC TNTC 55 3 2 hr — TNTC TNTC 126 23 — – TNTC TNTC 183 17 — 4 hr TNTC TNTC 88 12 — – TNTC TNTC 69 12 — – TNTC = too numerous to count Neutralization Control: 1:1 .times. 10.sup.8

D. Discussion

Results of the titer showed a viable B. subtilis spore concentration of 6.65.times.10.sup.8 spores per ml in the original suspension. Inoculation of 9.9 ml of disinfectant with 100 .mu.l of this suspension produced an initial concentration of 6.65.times.10.sup.6 spores per ml in the assay tube.

Results from these procedures allowed log reductions (LR) and Percent Kill (PK) values to be calculated. They are listed in the table below. Values were computed using the formulae: LR=-Log(S/So) and PK=(1-(S/So)).times.100; where S=concentration of organisms at a specific time; and So=the initial concentration of organisms at time zero.

TABLE-US-00003 Time LOG REDUCTION PERCENT KILL 30 min 0.090 18.8 1 hr 0.205 37.6 2 hr 0.634 76.8 4 hr 1.928 98.8

Neutralization control data showed that the disinfectant was adequately neutralized. Actual counts correspond to those resulting from dilution without appreciable killing.

The disinfectant preparation tested here displayed good sporicidal activity against B. subtilis spores. B. subtilis is a common species used in sporicidal testing and belongs to the same genus as the organism that causes anthrax. Because of their genetic similarities, B. subtilis spores have been used as a non-pathogenic surrogate for Bacillus anthracis, the anthrax bacterium. Therefore, these results are applicable to anthrax. It is expected that longer exposure would result in additional killing.

4. Evidence of Efficacy of 10 ppm Silver and 1.0% h.sub.2O.sub.2 Compositions and 14 ppm Silver and 1.5% H.sub.2O.sub.2 Composition against Bacillus Subtilis

A. Purpose of Example

The purpose of this example is to demonstrate the antimicrobial activity of two silver-based compositions of the present invention on bacterial endospores from the test organism Bacillus subtilis. This was accomplished by performing standard kill-time assays using a suspension of B. subtilis endospores. Viewed relative to the previous example (employing 22 ppm silver), this example establishes the promoting effect of hydrogen peroxide (H.sub.2O.sub.2) on the antimicrobial properties of silver compositions. Hydrogen peroxide is stable in the presence of the silver compositions of the present invention. While hydrogen peroxide has significant antimicrobial properties itself, it is frequently broken down by catalase or other microbial enzymes. However, the hydrogen peroxide is capable of weakening bacterial cell walls and enhancing entry of the silver particles before any enzymatic destruction of the hydrogen peroxide can occur.

B. Material and Methods

1 Test Organism. A test suspension containing endospores from Bacillus subtilis (ATCC #19659) was prepared from a culture grown on Nutrient Agar, to which additional sporulation enhancers were added. Plates were harvested with sterile water and endospores were purified by repeated centrifugations and resuspensions in water. The final wash was in 70% ethanol for 30 min, to ensure the death of all vegetative bacteria. The spores were resuspended in water containing 0.1% Tween.RTM. 80 (brand of polysorbate) to prevent clumping.

2 Neutralizer. The Neutralizer mixture consisted of 12.7% Tween 80, 6.0% Tamol.RTM. SN (brand of sodium salt of naphthalene-formaldehyde condensate), 1.7% lecithin, 1% Peptone, and 0.1% Cystine. This solution was intended to neutralize any chemicals so they would not affect subsequent growth of the bacteria.

3 Kill-Time Procedure:

a) A 9.9 ml aliquot of each of the disinfectants (inventive colloidal silver compositions: one containing 14 ppm silver and 1.5% H.sub.2O.sub.2; the other containing 10 ppm silver and 1 .0% H.sub.2O.sub.2) was placed in a sterile 20 mm.times.1 50 mm tube. The tubes were equilibrated in a 20.degree. C. water bath.

b) Each tube of disinfectant was inoculated with 100 .mu.l of the test organism suspension at time zero.

c) At 10 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr, one ml of organism/disinfectant suspension was removed to a tube containing nine ml of neutralizer. The tube was mixed thoroughly.

d) After two min, the neutralized suspension was serially diluted 1:10, in physiological saline solution (PSS).

e) The number of viable organisms in selected dilution tubes was assayed by membrane filtration. One ml aliquots were plated in duplicate. The membranes were washed with about 100 ml of sterile PSS and removed to Columbia Agar plates. The plates were incubated at 37.degree. C. for 20 hr.

f) The number of colonies on each filter was counted and log reductions computed.

4. Controls:

a) Titers of the test suspensions were computed by performing membrane filtration assays of selected 1:10 dilutions of the test suspensions in PSS.

b) A neutralizer control was performed by inoculating a mixture of 9 ml of neutralizer and 1 ml of disinfectant with 100 .mu.l of the 1:10.sup.3 dilution of the titer. This produced about 2,000 cfu/ml in the tube, which was allowed to stand for 20 minutes prior to diluting 1:10. Both tubes were assayed by membrane filtration using duplicate 1 ml. samples.

C. Results

TABLE-US-00004 Titer of Bacillus subtilis Spores: Dilution: 1:1 .times. 10.sup.6 1:1 .times. 10.sup.7 1:1 .times. 10.sup.8 Number of colonies: TNTC 36 5 TNTC 27 4 TNTC = too numerous to count.

TABLE-US-00005 Solution containing 14 ppm silver and 1.5% H.sub.2O.sub.2: Dilution of B. subtilis spore/disinfectant suspension: Time 1:1 .times. 10.sup.1 1:1 .times. 10.sup.2 1:1 .times. 10.sup.3 1:1 .times. 10.sup.4 1:1 .times. 10.sup.5 10 min — – TNTC TNTC 227 — – TNTC TNTC 265 30 min — – TNTC TNTC 258 — – TNTC TNTC 273 1 hr — – TNTC TNTC 55 — – TNTC TNTC 33 2 hr — TNC 207 29 — – TNC 237 24 — 4 hr 59 3 1 57 5 1 6 hr 0 0 0 3 0 0 8 hr 1 0 0 1 0 0 TNTC = too numerous to count.

Neutralization Control:

TABLE-US-00006 Undiluted 1:1 .times. 10.sup.1 TNTC 195 TNTC 210 TNTC = too numerous to count.

TABLE-US-00007 Solution containing 10 ppm silver and 1.0% H.sub.2O.sub.2: Dilution of B. subtilis spore/disinfectant suspension: Time 1:1 .times. 10.sup.1 1:1 .times. 10.sup.2 1:1 .times. 10.sup.3 1:1 .times. 10.sup.4 1:1 .times. 10.sup.5 10 min — – TNTC TNTC 230 — – TNTC TNTC 287 30 min — – TNTC TNTC 254 — – TNTC TNTC 260 1 hr — – TNTC TNTC 146 — – TNTC TNTC 124 2 hr — TNTC TNTC 64 — – TNTC TNTC 71 — 4 hr TNTC 72 5 TNTC 77 5 6 hr 0 0 0 2 0 0 8 hr 0 0 0 0 0 0 TNTC = too numerous to count.

Neutralization Control:

TABLE-US-00008 Undiluted 1:1 .times. 10.sup.1 TNTC 200 TNTC 184 TNTC = too numerous to count.

D. Discussion

The data showed a viable B. subtilis spore concentration of 2.59.times.10.sup.8 spores per ml in the original suspension. Inoculation of 9.9 ml of disinfectant with 100 .mu.l of this suspension produced an initial concentration of 2.59.times.10.sup.5 spores per ml in the assay tube.

Results from these procedures allowed log reductions (LR) and Percent Kill (PK) values to be calculated. They are listed in the following table. Values were computed using the formulae: LR=-Log(S/So) and PK=(1-(S/So)).times.100; where. S=concentration of organisms at a specific time; and So=the initial concentration of organisms at time zero. Since there was no significant kill within 30 min, the 10 min data was used for the So values. The 6 hr and 8 hr exposure times did not produce counts high enough to be reliable. Therefore, these data were not used in the linear regressions. Linear regressions were performed on the log reduction values using the `fitted line plots` command in the Minitab statistical software package. The regression equations produced, and the times required to effect a six-log reduction are shown along with the log reduction and percent kill values in the following table.

TABLE-US-00009 14 ppm SILVER + 10 ppm SILVER + 1.5% H.sub.2O.sub.2 1.0% H.sub.2O.sub.2 LOG PERCENT LOG PERCENT Time REDUCTION KILL REDUCTION KILL 30 min -0.03 -7.9 0.003 0.6 1 hr 0.66 78.0 0.28 47.8 2 hr 2.05 99.1 1.58 97.4 4 hr 4.63 99.998 3.54 99.97

Regression Analysis

Equation for 14 ppm calculated line: Y=-0.66704+1.32936x. Equation for 10 ppm calculated line: Y=-0.59690+1.03933x. These equations predict that the time for a 6-log reduction is 5.02 hrs for the 14 ppm composition and 6.35 hrs for the 10 ppm composition.

The neutralization control data showed that the disinfectant was adequately neutralized. Expected counts corresponded to those expected from the dilution.

The experimental disinfectant solutions tested exhibited significant sporicidal activity against B. subtilis spores. The B. subtilis strain used in these evaluations is the same one specified in the AOAC sporicidal test. Spores from this organism represent a significant challenge for most disinfectants. The times required to effect a six log reduction are in line with the sporicidal label claims of many cold sterilants.

5. Evidence of Efficacy of 10 ppm Silver Composition as a Broad Spectrum Antimicrobial

A. Methods

MIC (minimum inhibitory concentration) and MBC (minimum bactericidal concentration) tests were performed according to the standard broth microdilution method. The MIC is defined as the lowest concentration of an antibiotic that will inhibit the (in vitro) growth of an infectious organism. Results are reported in micrograms per ml. For medical antibiotics the interpretation of in vitro data is based on achievable serum concentrations of the drug, which may vary depending on dose, route of administration, degree of protein binding, site of infection, age and weight of the patient, and other factors. The MBC is defined as the lowest concentration of an antimicrobial agent needed to kill 99.9% of the initial organism inoculum.

The test was preformed by growing pure cultures of each of the test organisms in liquid culture. Turbidometric measurements were used to control the concentration of the culture. Serial dilutions of each test antibiotic were made in nutrient broth. The dilutions were calculated to cover the susceptible ranges for each organism for each agent. A standard amount of the test culture was added to each tube and the tube returned to an incubator (37.+-.2.degree. C.) for growth. The tubes were checked turbidometrically to determine bacterial growth. Below the MIC concentration the tubes showed an increase in optical density with time indicating bacterial growth. The lowest concentration of the antibiotic that showed no growth was the MIC. The “no growth” tubes were then subcultured in fresh medium. The “no growth” tube with the lowest concentration of antibiotic that showed no growth on subculturing was the MBC.

TABLE-US-00010 B. Results: Antimicrobial (ppm) Organism Tetracycline Ofloxacin Penicillin G Cefaperazone Erythromycin Silver S. pyogenes 0.625/>5 1.25/2.5 >5.0 0.313/1.25 0.003/0.019 2.5/5.0 S. mutans 0.625/>5 2.5/>5.0 0.521/>5 1.25/>5 .sup. 0.009/0.019 2.5/10.0 S gordonii 0.156/0.625 2.5/5.0 0.009/0.039 1.25/1.25 0.005/0.019 2:5/10.0 S. pnuemoniae 0.078/0.625 2.5/2.5 0.019/0.019 0.313/0.313 0.002/0.004 2.5/- 2.5 S. faecalis 0.313/>5 1.25/5.0 5.0/>5.0 >5.0 0.009/1.25 10.0/10.0 S. aureus 0.313/>5 0.417/0.625 2.5/>5.0 5.0/5.0 0.039/>5.0 .sup. 5.0/5.0 P. aeruginosa 0.078/5 0.156/0.313 0.13/>5.0 2.5/5.0 2.5/>5.0 1.67/5 E. coli .sup. 1.67/>5 0.104/0.156 >5.0 0.625/>5.0 .sup. 5.0/>5.0 2.5/2.5 E. aerogenes >5 0.078/0.156 >5.0 2.92/>5.0 >5.0 2.5/2.5 E. cloacae .sup. 1.67/>5 0.156/0.156 >5.0 >5.0 >5.0 2.5/5.0 S. typhimurium .sup. 1.25/>5 0.078/0.156 >5.0 1.25/2.5 5.0/>5.0 2.5/5.0 S arizona 0.625/>5 0.078/0.078 >5.0 0.833/>5.0 .sup. 4.17/>5.0 2.5/5.0 S. boydii .sup. 1.25/>5 0.078/0.156 >5.0 0.625/0.625 5.0/>5.0 1.25/1.25 K. pneumoniae 2.5/>5 0.417/0.625 >5.0 >5.0 >5.0 2.5/2.5 K. oxytoca .sup. 1.25/>5 10.104/0.156 >5.0 1.25/>5.0 >5.0 1.25/1.25

Data are presented as MIC/MBC (minimum inhibitory concentration/minimum bactericidal concentration) in parts per million (ppm)); “>” denotes that the concentration needed to obtain the MIC or the MBC was higher than test parameters measured for the test. For example, the highest concentration of tetracycline used on S. pyogene was 5 ppm. At that concentration there was still growth upon subculturing of the “no growth” tubes. Therefore, the MBC must be >(greater than) 5 ppm.

The MIC/MBC of E. coli strain 0 157:H7, which has been associated with outbreaks of hemorrhagic diarrhea and colitis, was determined in a subsequent study. The MIC was determined to be 2.5 ppm and the MBC was determined to be 5 ppm.

C. Conclusion

The 10 ppm silver composition of the present invention was tested and found to be both bacteriostatic and bactericidal for all organisms tested. In other studies, this composition was compared to other commercially available colloidal silver products and found to have a superior activity to all other preparations tested (data not shown). The most interesting observation was the broad spectrum that the 10 ppm silver composition possesses. The antimicrobial activity that was observed was fairly constant independent of the particular organism tested. With the exception of Streptococcus faecalis and Streptococcus aureus (which had MIC values of 10 ppm and 5 ppm, respectively), MIC values ranged between 1.25 ppm and 2.5 ppm for both gram positive and gram negative organisms. The MBC values behaved similarly with values ranging from 1.25 ppm to 5 ppm with the exception of Streptococcus mutans, Streptococcus gordonii, and Streptococcus faecalis (which all had MBC values of 10 ppm). The data suggest that 10 ppm silver embodiment of this invention exhibits an equal or broader spectrum of activity than any one antibiotic tested. Antibiotics generally have restricted antibacterial spectra limited to susceptible organisms, but as the data demonstrate, the silver composition of the present invention is equally effective against both gram positive and gram negative organisms. The data suggest that with the low toxicity associated with silver, in general, and the broad spectrum of antimicrobial activity of this silver composition, this preparation can be effectively used as an alternative to antibiotics.

D. Reference for Preceding Example

1 U.S. EPA IRIS Report for Silver-CASRN 7440-22-4

2 Fox C L, Modak S M. Mechanism of Silver Sulphadiazine Action on Burn Wound. Infections. Antimicrobial Agents Chemother. 5:582 588. 1974.

3. Furchner, J E, Richmond C R, and G A Drake. Comparative Metabolism of Radionuclides in Mammals. IV. Retention of Silver-110 m in the Mouse, Rat, Monkey, and Dog. Health Phys. 15:505 514.1968.

4. Grier, N. Silver and its Compounds in Disinfection, Sterilization, and Preservation. (Seymour S. Block, ed) 2.sup.nd Edn, pp 395 407. 1977.

5. Hindler, J A, and J H Jorgensen. Procedure in Antimicrobial Testing in Diagnostic Microbiology. (C R Mahon and G Manuselis, eds) pp 63 91. 1995.

6. Evidence of Efficacy of 32 ppm Silver Composition Against Pseudomonas Aeruginosa, Salmonella Choleraesuis and Staphylococcus Aureus

Pseudomonas aeruginosa ATOC #15442, Salmonella choleraesuis ATCC #10708 and Staphylococcus aureus ATCC #6538 were tested using the AOAC (Association of Official Analytical Chemists AOC Methods, vol. 1, 15th edition, 1990, AOAC Arlington, Va.) official methods 955.14, 95515 and 964.02. Nutrient broth (NBAOAC) tubes were inoculated from the stock culture, and the tubes incubated at 37.+-.2.degree. C. Transfers to fresh tubes of nutrient broth were made for three successive days with the final transfer being incubated at 37.+-.2.degree. C. for 48 54 hr. The Pseudomonas culture was decanted into a fresh tube to remove the pellicle. The other cultures were vortexed for 3 4 seconds and allowed to stand for 10 mm at room temperature. Finally the cultures were diluted 1:100 in peptone water (PEPW) to which equine serum was added to yield a 5% total organic challenge. Test carriers (10 mm long polished 304 stainless steel cylinders with an 8 mm outside diameter and 6 mm inside diameter) were soaked in challenge solution for 15 mm, removed, drained and dried at 37.+-.2.degree. C. for 40.+-.2 mm prior to use.

Phenol Resistance. Five-one ml aliquots of each dilution of the test phenol were placed into sterile test tubes and allowed to equilibrate in a 20.+-.2.degree. C. water bath. At 30 second intervals, 0.5 ml of each challenge culture was added to the appropriate dilutions of phenol, agitated, and replaced into the water bath: After the appropriate exposure times of 5, 10, and 15 minutes, a loopful of suspension was removed from the assay tubes and transferred to tubes of letheen broth (LETH). The tubes of LETH were incubated at 37.+-.2.degree. C. for 2 days.

Carrier Titration. For titration of carriers, 10 ml blanks of peptone Tween.RTM. (brand of polysorbate) (PEPT) solution were prepared. Two carriers were placed into the individual tubes, representing the first 1:10 dilution. The tubes were agitated vigorously enough to get bacteria into solution and serial dilutions were made into 9 ml blanks of LETH medium. The dilution blanks were incubated at 37.+-.2.degree. C. The last tube with growth indicated the log.sub.o titer of organisms on the carrier. AOAC requires carriers to have minimum populations of 1.times.10.sup.4 cfu/carrier.

Test of Silver Composition. Using sterile glass pipettes, 10 ml aliquots of the prepared disinfectants were placed into sterile test tubes and allowed to equilibrate in a refrigerated water bath held at 20.+-.2.degree. C. Without touching the sides of the test tubes, one contaminated dried carrier was added at 30 second intervals to each tube of silver composition and placed back into the water bath. For each organism the disinfectant was tested against 60 dried contaminated carriers at 5 and 10 minute exposure intervals. Following exposure, the carriers were removed from the disinfectant and transferred to a tube of LETH. The culture tubes were incubated at 37.+-.2.degree. C. for 2 days and scored as positive (+) or negative (0) for growth of the challenge organism.

Controls. For each organism, a dried contaminated carrier was added to a tube of LETH as a positive control. Uninoculated media tubes served as negative controls. After incubation, all negative tubes were spiked with 1 100 colony forming units (cfu) of the corresponding organisms to demonstrate neutralization efficacy. To demonstrate growth promotion of the media, the negative control tubes were also inoculated with the same 1 100 cfu for all three organisms. The inoculating volumes were plated in triplicate onto soybean casein digest agar (SCDA) to verify the inoculating titers. The tubes and plates were incubated at 37.+-.2.degree. C. until growth was seen in all tubes.

On the P. aeruginosa neutralization, the initial titer of inoculum was found to be >100 cfu which was too high for the protocol. Because all original tubes had been spiked, a simulated test was performed with same lot of media used in testing by placing carriers into disinfectant tubes from all three lots of silver compositions for 10 minutes. The carriers were sub-transferred to LETH blanks. These tubes were then spiked with 1 100 cfu of organism. The tubes were incubated as before and scored for growth or no growth. New tubes of sterile media from the same lot were also inoculated as a growth promotion verification.

B. Results

Initial testing using S. aureus demonstrated passing results for sample #1 and #2, but sample #3 failed. Upon investigation it was decided that sample #3 may have been damaged prior to shipment. A new bottle was obtained from the same lot as sample #3, and the new bottle was labeled as sample #4. The S. aureus challenge was repeated using sample #4. AOAC guidelines state that for any one time point and organism, only 1 carrier is allowed for growth for each lot tested.

Positive controls demonstrated growth and negative controls demonstrated no growth for all lots, time points, and organisms.

Carrier titration was run in duplicate for all organisms. The reported titer is an average of the replicates. For all three organisms, the average titer found on the carriers ranged from 5.5.times.10.sup.4 to 5.5.times.10.sup.6 cfu/carrier. AOAC requires carriers to have a minimum of 1.0.times.10.sup.4 cfu/carrier.

For P. aeruginosa 3/180 carriers showed growth at the 5 min test point and 2/180 carriers showed growth at the 10 min test point. For S. aureus 16/180 carriers showed growth at the 5 min test point and 2/180 carriers showed growth at the 10 min test point. For S. choleraesuis 6/180 carriers showed growth at the 5 min test point and 1/180 carriers showed growth at the 10 min test point.

The test Pseudomonas culture showed growth following a 5, 10 or 15 min treatment with 1:90 phenol and showed growth following a 5 or 10 min treatment with 1:80 phenol but no growth following 1 5 min treatment with 1:80 phenol. The Staphylococcus culture showed growth following a 5, 10 or 15 min treatment with 1:70 phenol and showed growth following 5 or 10 min treatment with 1:60 phenol but no growth following a 15 min treatment with 1:60 phenol. The Salmonella culture showed growth following a 5, 10 or 15 min treatment with 1:100 phenol but no growth following a 5, 10 or 15 min treatment with 1:90 phenol.

7. Evidence of Effectiveness of 32, 22, and 10 ppm Silver and 22 ppm Silver and 1.5% H.sub.2O.sub.2 and 10 ppm Silver and 10 ppm K.sub.2S.sub.2O.sub.8 Against Salmonella and Escherichia coli in Freshly Inoculated Beef Samples

A. Purpose of Example

The purpose of this example is to demonstrate the antimicrobial activity of the silver-based composition embodiments of the present invention on samples of beef flank steak inoculated on the exterior surface with a five strain cocktail of Salmonella species. or Escherichia coli O157:h7 at a high inoculum solution level (1.times.10.sup.6 cfu/cm.sup.2) and separately at a low inoculum solution level (1.times.10.sup.4 cfu/cm.sup.2) (cfu=colony forming unit).

B. Material and Methods

Beef Samples. Beef tissue samples were obtained from slaughter houses within 8 hours of evisceration. The rectus abdominus muscle was peeled off carcasses hanging in the chill cooler by making an incision between the 11.sup.th and 12.sup.th ribs and then peeling the muscle out along the natural seam. The aseptically retrieved samples were placed in plastic bags and on ice packs and were transported on the same day to the laboratory, where the samples were promptly packed in a Multi-Vac (A-300) and placed in a 4.degree. C. cooler. Samples used for testing had a pH between 5.8 and 6.0 and were no more than 36 hours post evisceration. From randomly selected rectus abdominus muscles, 13.times.8 cm samples were cut and treated. After treatment, a 3.5 cm.sup.2 flame sterilized stainless steel coring device and surgical scalpel were utilized to aseptically retrieve two meat cores per sampling interval from each sample. Tissue cores were placed in a sterile stomacher bag with 25 ml of 0.1% peptone and were mixed for two minutes in a stomacher (Lab Bender 400). Serial dilutions were prepared and spiral plated at 0 minutes, 20 minutes, 1 hour, 4 hours, and 24 hours post-treatment on selective and recovery media.

Bacterial Cultures. Bacterial cultures were obtained from the Kansas State University (KSU) stock culture collection and were stored using the “Protected Bead” storage system. The following cultures were used for the Salmonella specimen: S. lille (UGA), S. montevideo (UGA), S. typhimurium (UGA), S. agona (KSU 05 from CDC outbreak isolate), and S. newport (KSU 06 CDC outbreak isolate). The following cultures were used for the Escherichia coli specimen: E. coli O157:H7 (CDC 01,03), E. coli O157:H7 (USDA-FSIS 011-82 Rif resistant 100 ppm), E. coli O157:H7 (ATCC 43895 HUS associated Type I & II toxins Rif. Res.) and E. coli ATCC #23740 (Genotype K-12 prototrophic lambda).

Stock cultures were cultivated by placing one impregnated bead into a 5 ml solution of Difco.RTM. Tryptic Soy Broth (TSB) and incubating for 24 hours at 35.degree. C. Next, a 0.05 ml loop of the respective culture was inoculated into a 5 ml solution of TSB and incubated for 24 hour at 35.degree. C. to obtain a pure culture. After incubation, 1 ml of the respective culture was inoculated into 49 ml TSB and incubated for 24 hours at 35.degree. C. Following incubation, samples were centrifuged (15,300.times.g at 4.degree. C.), and the supernatant material decanted and the pellet was re-suspended with 50 ml of 0.1% peptone and centrifuged (15,300.times.g at 4.degree. C.) a final time. The peptone was decanted and the remaining pellet was re-suspended with 10 ml of 0.1% peptone. The five 10 ml bottles of respective culture were mixed together to create a 50 ml cocktail containing 10.sup.9 cfu/ml of Salmonella species. The cocktail was diluted to 10.sup.6 cfu/ml or 10.sup.4 cfu/ml using 0.1% peptone. Cultures were confirmed by cultivation on selective and differential media, and biochemical analysis of presumptive colonies using API 20E kits.

Method of Inoculation. Samples of beef flank steak (rectus abdominus muscle) were trimmed to 13.times.8 cm (104 cm.sup.2) and were inoculated with a five strain cocktail of Salmonella species. or Escherichia coli O157:h7 at a high inoculum solution level (10.sup.6 log cfu/cm.sup.2) and separately at a low inoculum solution level (10.sup.4 log cfu/cm.sup.2). This inoculum was misted onto the tissue surface using a plastic spray bottle with samples contained within a sealed inoculum chamber. The actual Salmonella species. concentration on the meat surface was approximately 5.0 and 3.4 log cfu/cm.sup.2 for the high and low level inoculum solution, respectively. For E. coli O157:H7, the respective meat surface inoculation levels were 4.2 and 3.9 log cfu/cm.sup.2.

The beef samples were then hung vertically on stainless steel hooks attached to a motorized track that pulled the beef samples through a model spray cabinet (Kansas State University, Food Safety Laboratory) while spray treatments were applied. Treatments with either the silver compositions of this invention or deionized water were applied to the beef at 20 psi from a distance of 13 cm in the model pressure rinse cabinet for 20 seconds. The spray nozzle (BETE NF0580 303) delivered approximately 20 ml of solution to the surface of the beef sample. The temperature of solutions and treatment application room was approximately 14.degree. C. After treatment, duplicate 3.5 cm.sup.2 core samples were randomly drawn from the lateral surface of the beef sample at 0, 20, 60 and 240 minutes. Samples were cultivated and enumerated on selective differential and recovery media. Log reductions were calculated by subtracting the log.sub.10 of cfu/cm.sup.2 of the inoculated/treated samples at the specified sampling times (0, 20, 60, and 240 minutes) from the log.sub.10 of cfu/cm.sup.2 of the inoculated/untreated samples at 0 minutes. Sample treatment included the use of 32 ppm silver, 22 ppm silver, and 10 ppm silver compositions according to the present invention. Separately, combinations of 22 ppm Ag with 1.5 wght % hydrogen peroxide and 10 ppm Ag with 10 ppm peroxydisulfate (K.sub.2S.sub.2O.sub.8) were tested.

C. Results with 32 ppm Silver Composition

The use of a composition of 32 ppm silver according to this invention produced a reduction in bacteria on beef steak. In the following, this reduction is expressed as the log.sub.10 of the ratio of the number of bacteria in the control at time 0 to the amount of bacteria in the treated specimen at the sampling (i.e., treatment) time.

For Salmonella, at the lower initial bacteria level (10.sup.4), the following log reductions were recorded: 0.78 at 0 minutes, 1.11 at 20 minutes, 1.08 at 60 minutes, and 1.23 at 240 minutes. Thus, at 4 hours (240 minutes), the ratio of the initial bacteria count in the control to bacteria in the sample treated with 32 ppm silver is 10.sup.1.23. For the higher initial bacteria level (10.sup.6), the following log reductions were recorded: 0.86 at 0 minutes, 0.95 at 20 min, 0.98 at 60 min and 1.17 at 240 min. The results indicate that the 32 ppm silver embodiment of this invention shows an effective bactericidal effect for Salmonella on beef steak. It will be appreciated that disinfecting a meat surface is an extreme challenge for any disinfectant.

For E. coli, for the lower initial bacteria level (10.sup.4), the following log reductions were recorded: 1.03 at 0 minutes, 1.28 at 20 minutes, 1.42 at 60 minutes, and 1.58 at 240 minutes. For the higher initial bacteria level (10.sup.6), the following log reductions were recorded: 0.65 at 0 minutes, 0.60 at 20 minutes, 0.83 at 60 minutes and 0.87 at 240 minutes. The results indicate that the 32 ppm silver embodiment of this invention shows an effective bactericidal effect for pathogenic E. coli on beef steak.

D. Results with 22 ppm Silver Composition

Results with Silver in Water. For Salmonella at the lower initial bacteria level (10.sup.4), the following log reductions were recorded: 0.41 at 0 minutes, 0.43 at 20 minutes, 0.48 at 60 minutes, and 0.68 at 240 minutes. For the higher initial bacteria level (10.sup.6), the following log reductions were recorded: 0.24 at 0 minutes, 0.24 at 20 minutes, 0.42 at 60 minutes and 0.61 at 240 minutes. The results indicate that the 22 ppm silver embodiment of this invention furnishes an effective bactericidal effect for Salmonella on beef steak.

Results with Silver in water and 1.5 wght % hydrogen peroxide. For Salmonella, for the lower initial bacteria level (10.sup.4), the following log reductions were recorded: 0.34 at 0 minutes, 0.33 at 20 minutes, 0.36 at 60 minutes, and 0.62 at 240 minutes. For the higher initial bacteria level (10.sup.6), the following log reductions were recorded: 0.28 at 0 minutes, 0.14 at 20 minutes, 0.30 at 60 minutes and 0.69 at 240 minutes. The results indicate that the 22 ppm silver with 1.5 wght % hydrogen peroxide embodiment of this invention provides an effective bactericidal effect for Salmonella on beef steak.

E. Results with 10 ppm Silver Composition

Results with Silver Composition in Water. For Salmonella, for the lower initial bacteria level (10.sup.4), the following log reductions were recorded: 0.38 at 0 minutes, 0.41 at 20 minutes, 0.39 at 60 minutes, and 0.61 at 240 minutes. For the higher initial bacteria level (10.sup.6), the following log reductions were recorded: 0.24 (at 0 minutes, 0.21 at 20 minutes, 0.41 at 60 minutes and 0.54 at 240 minutes. The results indicate that the 10 ppm silver embodiment of this invention provides an effective bactericidal effect for Salmonella on beef steak.

Results with Silver Composition in Water with 10 ppm K.sub.2S.sub.2O.sub.8. For Salmonella, for the lower initial bacteria level (10.sup.4), the following log reductions were recorded: 0.26 at 0 minutes, 0.28 at 20 minutes, 0.35 at 60 minutes, and 0.58 at 240 minutes. For the higher initial bacteria level (10.sup.6), the following log reductions were recorded: 0.03 at 0 minutes, 0.16 at 20 minutes, 0.21 at 60 minutes and 0.36 at 240 minutes. The results indicate that the 10 ppm silver with 10 ppm potassium peroxydisulfate (K.sub.2S.sub.2O.sub.8) embodiment of this invention provides an effective bactericidal effect for Salmonella on beef steak.

8. Evidence of Effectiveness of 10 ppm Silver for Treatment of Human Ailments

A. Purpose of Example

The purpose of this example is to demonstrate the utility of silver-based composition embodiments of the present invention for treating a variety of human ailments. The studies in this section were performed in Ghana, West Africa, at the Air Force Station Hospital under the direction of Dr. Kwabiah, at the Korie-Bu Teaching Hospital under the direction of Sr. Sackey, and at the Justab Clinic/Maternity Hospital under the direction of Dr. Abraham. In total, fifty-eight (58) patients were treated using a composition of the present invention comprising 10 ppm silver. The composition was used both internally and externally as an alternative to traditional antibiotics. The ailments treated included malaria, upper respiratory tract infections, urinary tract infections, sinusitis, vaginal yeast infections, eye, nose and ear infections, cuts, fungal skin infections, and sexually transmitted diseases, such as gonorrhea.

B. Treatment Methods and Outcomes

Abdominal pain and Diarrhea. The method comprises the step of administering approximately 5 25 ml of silver composition, one to five times a day orally until there was a response. One patient was treated with about 10 ml (about two teaspoons) of a composition of the present invention three times in one day. The patient had a full recovery in one day.

Bronchitis. The method comprises the step of administering ca. 2 25 ml of silver composition orally, one to five times a day until there was a response. Two patients were treated with about 5 ml (about one teaspoon) each of a composition of the present invention for two times a day for three days. The patients had a full recovery in three days.

Vaginal Yeast (Candida). The method comprises the step of administering ca. 5 25 ml of silver composition, one to five times a day as vaginal douches until there was a response. Five patients were treated with about 10 ml (about two teaspoons) each of a composition of the present invention for two times per day. The patients showed a full recovery within six days.

Conjunctivitis. The method comprises the step of administering ca. several drops of a silver composition, one to five times a day to the infected eye until there was a response. Two patients were treated with several drops of a composition of the present invention in each of the infected eyes for two times per day. The patients had a full recovery after one day.

External cuts and infection (including Staphylococcus skin infections, septic ulcers and infected abscesses). The method comprises the step of administering a silver composition, one to five times a day to the infected area until there was a response. Six patients were treated with about 5 ml (about one teaspoon) each of a composition of the present invention on the infected areas for two times per day. The patients showed a full recovery within three days.

External Otitis. The method comprises the step of administering a silver composition, one to five times a day to the infected ear until there was a response. Six patients were treated with approximately two drops of a composition of the present invention into the infected ears for three times per day. The patients showed a full recovery after about four days.

Otitis Media. The method comprises the step of administering a silver composition, one to five times a day to the infected ear until there was a response. One patient was treated with approximately two drops of a composition of the present invention comprising into the infected ear three times per day. The patient showed a full recovery in four days.

Fungal Skin Infection. The method comprises the step of administering a silver composition, one to five times a day topically to the infected area until there was a response. Two patients were treated with about ten ml (two teaspoons) each of a composition of the present invention three times per day. The patients showed a full recovery within eight days.

Gonorrhea. The method comprises the step of administering a silver composition to the infected area until there was a response. Two patients were each treated with about ten ml (two teaspoons) of a composition of the present invention three times per day. The patients showed an absence of symptoms within six days.

Malaria. The method comprises the step of administering a silver composition, one to five times a day orally to the patient until there was a response. Eleven patients were treated with about ten ml (two teaspoons) each of a composition of the present invention three times per day. The patients showed a resolution of symptoms within five days.

Halitosis and Gingivitis. The method comprises the step of administering a silver composition, one to five times a day as a mouthwash until there was a response. Two patients were each treated with the composition as a mouthwash. There was a full resolution of symptoms within three days (gingivitis) and within one day (halitosis).

Pelvic Inflammatory Disease. The method comprises the step of administering about 5 25 ml of silver composition, one to five times a day as a vaginal douche until there was a response. One patient was treated with about 5 ml (approximately one teaspoon) of a composition of the present invention two times per day. The patient’s symptoms resolved within five days.

Pharyngitis. The method comprises the step of administering a silver composition, one to five times a day as a gargle until there was a response. Four patients were each treated with about ten ml (two teaspoons) of a composition of the present invention three times per day. The patients showed full recovery within six days.

Retrovirus Infection (HIV). The method comprises the step of administering a silver composition, comprising 5 to 40 ppm silver one to five times a day orally area until there was a response. One patient exhibiting HIV (human immunodeficiency virus )was treated with about 5 ml (approximately one teaspoon) of a composition of the present invention two times per day. The patient’s symptoms resolved within five days.

Sinusitis and Rhinitis. The method comprises the step of administering a silver composition, one to five times a day to the nose until there was a response. Six patients with nasal infections (four with sinusitis and two with rhinitis) were each treated with approximately two drops of a composition of the present invention comprising in their nasal passages three times per day. The patients showed full recovery within four days.

Tonsillitis. The method comprises the step of administering a silver composition, one to five times a day as a gargle until there was a response. One patient was treated with a composition of the present invention three times per day. The patient showed full recovery within seven days.

Upper Respiratory Tract Infection. The method comprises the step of administering a silver composition, one to five times a day orally until there was a response. Two patients were each treated with about 5 ml (approximately one teaspoon) of a composition of the present invention three times per day. The patients showed full recovery within six days.

Urinary Tract Infections. The method comprises the step of administering a silver composition, one to five times a day orally until there was a response. Three patients were each treated with about ten ml (two teaspoons) of a composition of the present invention two to three times per day. The patients showed full recovery within six days.

C. Discussion

These results are consistent with the various in vitro tests reported herein. Essentially, the silver composition is extremely effective against a large number of microbes in vitro. However, the tests indicate that this effectiveness remains even in the presence of a large amount of organic material. The silver compositions are widely effective in vivo where the organic background is extremely high. Many other disinfecting agents are ineffective in the presence of a large amount of organic material and/or are too caustic or toxic to be used in vivo.

9. Evidence of Efficacy of 10 ppm Silver Against Tuberculosis Bacteria

A. Purpose

The purpose of this example is to demonstrate the efficacy of a silver composition of the present invention against the bacteria that cause tuberculosis. This example describes the procedures for evaluation of the present invention for tuberculocidal efficacy. The methodology is based on the Tuberculocidal Activity Test Method as accepted by the EPA on Dec. 11, 1985. [Refer to United States Environmental Protection Agency, 1986. Office of Pesticides and Toxic Substances. Data Call-In Notice for Tubercuolocidal Effectiveness Data for All Antimicrobial Pesticides with Tuberculocidal Claims. (Received Jun. 13, 1986).

B. Material and Methods

Materials. The silver composition of the present invention comprised 10 ppm silver in water. The silver composition was evaluated employing a liquid to liquid matrix against Mycobacterium bovis BCG (TMC 1028). This organism causes tuberculosis in animals and can cause tuberculosis in humans. It is used as a “stand-in” for M. tuberculosis, the major cause of human tuberculosis, as tests have shown it to have a similar susceptibility to M. tuberculosis. The test organism was exposed to the silver composition in duplicate at four exposure times and quantified using membrane filtration.

Procedure. A vial of frozen stock culture was removed from storage and thawed. An equal volume of buffered gelatin (BUGE) was added to the cell suspension and homogenized with a Teflon.RTM. (brand of polytetrafluoroethylene) tissue grinder for 1 minute while keeping the culture at 0 to 4.degree. C. in an ice bath. The homogenized cell suspension was diluted with saline Tween.RTM. 80 (brand of polysorbate) solution (ST80) to approximately 10.sup.7 cfu/ml.

Challenge Titration. Tenfold serial dilutions of the culture were prepared in dilution blanks containing 9 ml of neutralizer broth (NEUB) through a 10.sup.-6 dilution. Three 1 ml aliquots of the appropriate dilutions were membrane filtered by first adding 10 20 ml physiological saline solution (PHSS) to the filter housing and then adding a 1 ml aliquot of the appropriate dilution. The filter was then rinsed with approximately 100 ml of PHSS. The filters were aseptically removed from the filter housing and placed onto 7H11 agar plates. The plates were incubated in a humidified chamber at 37.+-.2.degree. C. for 21 days.

Positive Control. A tube containing 9 ml of ST80 was prepared and equilibrated to 20.+-.0.5.degree. C. At time 0, 1 ml of test organism culture was added to the tube (1:10 dilution). The sample was held for 60 minutes. Tenfold serial dilutions were prepared in dilution blanks containing 9 ml of NEUB through 10.sup.-6 dilution. Three 1 ml aliquots of the appropriate dilutions were membrane filtered by first adding 10 20 ml PHSS to the filter housing and then adding a 1 ml aliquot of the appropriate dilution. The filter was rinsed with approximately 100 ml PHSS. The filters were aseptically removed from the filter housing and placed onto 7H11 agar plates. The plates were incubated in a humidified chamber at 37.+-.2.degree. C. for 21 days.

Tests. Two 25.times.150 mm tubes containing 9 ml of the test sample were equilibrated to 20.+-.0.5.degree. C. in a water bath. To each tube containing the test disinfectant (i.e., silver composition), 1 ml of test organism culture was added. The tube was mixed by swirling and placed back into the water bath. At 15, 30, 45, and 60 minutes, 1.0 ml aliquots of the disinfectant-cell suspension were transferred to 9 ml of NEUB and mixed thoroughly. Tenfold serial dilutions were prepared in dilution blanks containing 9 ml of NEUB through the 10.sup.-6 dilution. Three 1 ml aliquots of the appropriate dilutions were membrane-filtered by first adding 10 20 ml PHSS to the filter housing and then adding a 1 ml aliquot of the appropriate dilution. The filter was rinsed with approximately 100 ml PHSS. The filters were aseptically removed from the filter housing and placed onto 7HII agar plates. The plates were incubated in a humidification chamber at 37.+-.2.degree. C. for 21 days.

Phenol Control. To demonstrate minimum culture viability and resistance, the culture was tested against a 0.8% phenol solution. A 1 ml aliquot of test organism culture was placed into 9 ml of the phenol solution equilibrated to 25.+-.0.5.degree. C. and incubated for 20 minutes. After the exposure period, 1 ml from the phenol/organism solution was removed and added to 9 ml of NEUB. Tenfold serial dilutions were prepared in dilution blanks containing 9 ml of NEUB through 10.sup.-6 dilution. Three 1 ml aliquots of the appropriate dilutions were membrane filtered by first adding 10 20 ml PHSS to the filter housing and then adding a 1 ml aliquot of the appropriate dilution. The filter was rinsed with approximately 100 ml PHSS. The filters were aseptically removed from the filter housing and placed onto 7H11 agar plates. The plates were incubated in a humidified chamber at 37.+-.2.degree. C. for 21 days.

Neutralization verification. A 1 ml aliquot of the disinfectant was added to 8 ml of NEUB. The disinfectant/neutralizer broth was allowed to equilibrate to the same temperature as the test samples. One ml of test organism culture was added to the mixture and mixed thoroughly. Incubation was continued for the approximate time it would take to filter a sample. Additionally, a 1 ml aliquot of test organism was added to 9 ml of NEUB and mixed thoroughly (1:10 dilution). Tenfold serial dilutions of both tubes were prepared in dilution blanks containing 9 ml of NEUB thought 10.sup.-6 dilution. Three 1 ml aliquots of the appropriate dilutions were membrane filtered by first adding 10 20 ml PHSS to the filter housing and then adding a 1 ml aliquot of the appropriate dilution. The filter was rinsed with approximately 100 ml PHSS. The filters were aseptically removed from the filter housing and placed on 7H11 agar plates. The plates were incubated in a humidified chamber at 37.+-.2.degree. C. for 21 days.

C. Results

The starting titer for the challenge culture was 4.7.+-.10.sup.7 cfu/ml. The positive control titer was 6.5.times.10.sup.6 cfu/ml. The media used in this study effectively demonstrated neutralization with a 95.2% recovery in a disinfectant/neutralizer solution when compared to a media blank.

For the test plates, expected counts were underestimated and therefore the reported counts exhibit “>” to mark that the count is an estimation and that accurate counts are beyond the limit of detection for the dilutions plated.

In calculating the log and percent reductions of the disinfectant against M. bovis, the estimated counts which have “greater than” counts resulted in “less than” log and percent reductions (“< "). The purpose of this is to demonstrate that the results are an estimation and beyond the accurate limit of detection for the dilutions plated. All reductions were calculated using the positive control as the initial starting titer of the organism. The results for log and percent reductions are summarized below. As a measure of the resistance of the challenge culture, the phenol resistance of the M. bovis showed a .about.1.81 log reduction with 20 minutes of exposure to 0.8% phenol. Replicate One: TABLE-US-00011 Exposure time Log reduction Percent reduction 15 minutes <0.12 <12.3% 30 minutes <0.22 <40.0% 45 minutes <1.57 <97.2% 60 minutes <1.56 <97.2% Replicate Two: TABLE-US-00012 Exposure time Log reduction Percent reduction 15 minutes <0.26 <44.8% 30 minutes <0.20 <36.9% 45 minutes <1.58 <97.3% 60 minutes <1.53 <97.1% D. Conclusions The use of silver compositions of the present invention is effective against tuberculosis bacteria. A method comprising the step of administering silver compositions of the present invention is effective against tuberculosis organisms. 10. Evidence of Efficacy of 10 ppm Silver Against Candida Albicans ATCC #10231, Trichomonas vaginalis ATCC #20235, and MRSA Staphyloccocus aureus ATCC #BAA-44 A. Purpose of Example The purpose of this example is to illustrate the efficacy of silver compositions of the present invention against Candida albicans ATCC10231, Trichomonas vaginalis ATCC 20235, and drug resistant Staphylococcus aureus ATCC BAA-44. Candida albicans, a yeast, and Trichomonas vaginalisis, a protozoa, can cause numerous health problems including vaginal infections, diaper rash, and thrush. The results below show that silver compositions of the present invention produced nearly a 100% kill of both organisms. The results show the utility of silver compositions of the present invention in a feminine hygiene product and in a diaper rash product. Staphylococcus aureus can cause serious blood poisoning when it enters a wound. It once was easily treated with penicillin, but the organism has now mutated to the point where it is totally resistant to penicillin. The next defense on the antibiotic ladder has been methicillin, but methicillin-resistant strains have become increasingly common, especially in hospitals. These strains are known as MRSA (methicillin-resistant Staphylococcus aureus) and have been dubbed the "superbug." People who contract MRSA can die in a matter of days. In the results reported in this example, a silver composition of the present invention was found to kill 91.6% of the MRSA in just 10 minutes, and 99.5% in an hour. The results show the utility of silver compositions of the present invention in killing MRSA, a known infectious threat. B. Methods and Results Employing the USP Preservative Rapid Challenge Test with a composition of the present invention comprising 10 ppm silver in water, the following results were obtained. These results show that silver compositions of the present invention can be effective against yeast infections, protozoa infections, and drug resistant bacteria infections. Candida albicans ATCC #10231. The initial concentration of Candida albicans yeast was 6.8.times.10.sup.5 cfu/ml. After contact for either 10 minutes, 30 minutes, 1 hour, or one day with the silver composition, there were no colonies detected. Trichomonas vaginalis ATCC #30235. The initial concentration of Trichomonas vaginalis protozoa was 6.0.times.10.sup.4 cfu/ml. After contact with the silver composition for either 10 minutes, 30 minutes, 1 hour, or one day, there was 0% motility of 100 Organisms. That is, one hundred (100) Trichomonas vaginalis parasites were analyzed via microscopy for motility of flagella. None of the one-hundred (100) parasites demonstrated motility after only ten (10) minutes of contact with the silver composition indicating inhibitory or lethal properties of the silver composition on the parasites. The outer membranes of twenty-five (25) percent of the parasites had ruptured after contact of one (1) day. Staphylococcus aureus MRSA ATCC #BAA-44. The initial concentration of methicillin-resistant Staphylococcus aureus (MRSA) was 6.0.times.10.sup.6 cfu/ml. After contact with the silver composition, there were 500,000 cfu/ml detected after 10 minutes contact (91.6% killed), 70,000 cfu/ml after 30 minutes contact (98.8% killed), 30,000 cfu/ml after 1 hour contact (99.5% killed), and fewer than 10 cfu/ml after one day contact (virtually total kill). 11. Evidence of the Efficacy and Lack Cytotoxicity of 10 ppm Silver, 14 ppm Silver+1.5% H.sub.2O.sub.2, and 22 ppm Silver in Inhibiting DNA Polymerase and Reverse Transcriptase in the Context of Hepatitis B A. Purpose of Example The purpose of the example is to illustrate the efficacy of silver compositions of the present invention against hepatitis B. This example shows that silver compositions of the present invention have antiviral properties. Any agent used in antiviral therapy should exhibit little or no cytotoxicity so cytotoxicity of the silver compositions was analyzed. Hepatitis B is caused by a DNA virus of the hepadnaviridae family of viruses. The Hepatitis B Virus (HBV) is a 3.2 kb DNA virus, replicating almost exclusively in the liver cells (hepatocytes). Replication involves two main enzymes: DNA polymerase and reverse transcriptase. The results of this example show that silver compositions of the present invention interfere with replication involving either DNA polymerase or reverse transcriptase. The results of this example show that silver compositions of the present invention have antiviral properties. The results of this example show that silver compositions of the present invention can be effective against hepatitis B. As further detail, when hepatitis B enters the body of a new host, it infects the liver if it gets past the host's immune system. In the infection, the virus attaches to the membrane of a liver cell, and the core particle of the virus enters the liver cell. The core particle then releases its contents of DNA and DNA polymerase into the liver cell nucleus. Within the liver cell, the virus replicates via reverse transcription and translation processes, which involve reverse transcriptase and DNA polymerase enzymes. The DNA polymerase causes the liver cell to make copies of hepatitis B DNA. These copies of the virus are released from the liver cell membrane into the blood stream. From there, they can infect other liver cells and thus replicate effectively. The incubation period of the hepatitis B virus is about 6 to 25 weeks (i.e., time before physical and generally detectable histological or physical symptoms occur). However, there are several biochemical and histological changes that occur in the early stages following infection with the hepatitis B virus. B. Materials Solutions comprising 10 ppm, 14 ppm, 22 ppm, and 32 ppm silver compositions according to the present disclosure were used. The nucleotides dATP, dGTP, dCTP, and [.sup.3H]-dTTP were obtained from standard commercial sources, as were the compounds lamivudine (a synthetic antiretroviral agent) and zidovudine (AZT). Isolated Hepatitis B virus was freshly obtained from a person suffering from Hepatitis B infection and was taken up by Haffine Institute, Mumbai INDIA(a WHO certified testing laboratory). Test cell cultures (Vero and Hep2) were grown as confluent monolayers by typical cell culture methods. C. Methods 1) Procedure for Test of DNA Polymerase Inhibition. Overall approach. Hepatitis B viral extracts from human subjects are incubated with radiolabelled nucleotides and an active inhibitor. Percent inhibition is calculated based on the amount of de novo viral nucleic acid synthesized with respect to lamivudine as a positive control and phosphate buffer saline (PBS) as a negative control. Specific procedure. Isolated Hepatitis B virus was lysed to extract free polymerase enzyme, which is free from contaminating enzymes. A virus extract (25 .mu.l) was added to a reaction mixture comprising dATP, dGTP, dCTP and [.sup.3H]dTTP nucleotides (25 .mu.l). Active inhibitor (3 .mu.l) was added to the mixture comprising virus extract and nucleotides. The resultant mixture was incubated at 37.degree. C. for 2 hours. A separate negative control experiment was performed in which phosphate buffer saline (PBS, 3 .mu.l) was used instead of the inhibitor (3 .mu.l). A separate positive control experiment was performed in which a known DNA polymerase inhibitor (3 .mu.l of lamivudine at a concentration 3 mg/ml) was used instead of the tested inhibitor (3 .mu.l). The reaction was stopped by adding 25 .mu.l EDTA and 25 .mu.l TCA (trichloroacetic acid). The reaction mixture was then spotted on ionic paper (DEAE paper). The paper was washed three times with TCA and then with ethyl alcohol. The filter paper was air dried and put into a scintillation vial with a scintillation cocktail. Radioactivity was measured by a liquid scintillation counter (Blue Star). As a counting control, a blank silver composition was run through the complete procedure without viral load, to check any potential interference in the scintillation counter method. A reference for this method is P. S. Venkateswaran, I. Millman, and B. S. Blumberg, "Effect of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies," Proc. Natl. Acad. Sci., USA, 1987, 84, 274 278, which is incorporated herein by reference. 2) Procedure for Test of Reverse Transcriptase Inhibition. A commercial viral enzyme preparation of Moloney murine leukemia virus reverse transcriptase (MoMuLV) having Poly(A)dT (primer for RT) was used. 50 .mu.l of the MoMuLV preparation was combined with a mixture of dATP, dGTP, dCTP and [.sup.3H]dTTP nucleotides. This mixture was combined with 3 .mu.l of the inhibitor to be tested, and the resultant mixture was incubated at 37.degree. C. for 2 hours. A negative control experiment was performed in which phosphate buffer saline (PBS, 3 .mu.l) was used instead of the inhibitor. A positive control experiment was performed in which a known reverse transcriptase inhibitor (3 .mu.l of AZT at a concentration 0.625 microgram/ml) was used instead of the tested inhibitor. The reaction was stopped by adding 25 .mu.l EDTA and 25 .mu.l TCA. The reaction mixture was then spotted on ionic paper (DEAE paper). The paper was washed three times with TCA and then with ethyl alcohol. The filter paper was air dried and put in a scintillation vial with a scintillation cocktail. Radioactivity was measured by a liquid scintillation counter (Blue Star). 3) Procedure for Testing Cytotoxicity. Cells were prepared from healthy, confluent Vero and Hep2 cell cultures that were maintained by passage every 3 4 days. One day prior to the test cells were released from the cultures using standard techniques and suspended in a growth medium and dispensed into wells of a microtiter plate and placed in a 5% CO.sub.2 incubator at 37.+-.2.degree. C. An aliquot (100 .mu.l) of each test substance was introduced into a well (in triplicate) with 100 .mu.l of PBS as a control. Every 24 hrs the wells were examined under high power of an inverted microscope to check for any cytopathic effect (CPE). D. Results Results for test of reverse transcriptase inhibition: TABLE-US-00013 Sample % Inhibition negative control (PBS) 0 positive control (AZT) 31.33 Silver, 10 ppm 89.52 Silver, 14 ppm and 1.5% H2O2 86.93 Silver, 22 ppm 84.46 Results for test of DNA polymerase inhibition: TABLE-US-00014 Sample % Inhibition negative control (PBS) 0 positive control (Iamivudine) 31.33 Silver, 10 ppm 77.73 Silver, 14 ppm with 1.5% H2O2 65.6 Silver, 22 ppm 60.89 Silver compositions of the present invention are highly effective at inhibiting DNA polymerase Results for test of reverse transcriptase inhibition: TABLE-US-00015 Sample % Inhibition negative control (PBS) 0 positive control (AZT) 18.06 Silver, 10 ppm 89.52 Silver, 14 ppm with 1.5% H2O2 86.93 Silver, 22 ppm 84.46 Thus, silver compositions of the present invention inhibit reverse transcriptase. Silver compositions of the present invention would be expected to be effective against human ailments propagated by viruses, such as hepatitis B. Results for test of cytotoxicity: TABLE-US-00016 Sample Vero Hep2 control (PBS) No CPE No CPE Silver, 10 ppm No CPE No CPE Silver, 14 ppm with 1.5% H2O2 CPE positive CPE positive Silver, 22 ppm No CPE No CPE These results indicate that the silver composition is essentially non-cytotoxic. As expected, hydrogen peroxide, which is known to be cytotoxic, shows a cytotoxic effect. Thus, the silver should be harmless to cells when used in vivo. 12. Evidence of Efficacy of Silver Composition as Water Disinfectant A. Purpose Tests were carried out to demonstrate the efficacy of the inventive composition in disinfecting drinking water. B. Methods A sample of raw river water was spiked with two loopfuls of Klebsiella oxtyoca. 100 ml aliquots of this of this spiked water solution were brought to 0.05 ppm, 0.1 ppm, 0.2 ppm, 0.5 ppm, or 1.0 ppm of inventive silver composition. After an incubation of 5 60 minutes, the samples were membrane filtered. The filter was rinsed with approximately 100 ml sterile water. The filters were aseptically removed from the filter housing and placed on coliform nutrient agar plates. The plates were incubated under growth conditions for 24 hours and counted. TABLE-US-00017 Total Coliform (per Sample Silver (ppm) Contact (min) ml) Cfu/100 ml raw water -- -- 36 TNTC 1 1.00 5.0 0 0 2 1.00 10.0 0 0 3 1.00 15.0 0 0 4 1.00 30.0 0 0 5 0.50 10.0 0 0 6 0.50 30.0 0 0 7 0.50 60.0 0 0 8 0.20 5.00 0 0 9 0.20 10.0 0 0 10 0.20 30.0 0 0 11 0.20 60.0 0 0 12 0.10 10.0 0 0 13 0.05 20.0 0 0 TNTC = too numerous to count. The silver composition proved to be surprisingly effective. Even at the shortest time (20 min) allowed for incubation of the lowest concentration tested (0.05 ppm) there was a complete kill of the bacteria. At 0.20 ppm and higher there was a complete kill at 5 minutes. It seems clear that a complete kill takes less than 5 minutes. 13. Evidence of Efficacy of 32 ppm Silver as Surface Disinfectant The Environmental Protection Agency (EPA) has approved a 32 ppm silver composition of the present invention as a broad spectrum surface disinfectant for use in hospitals, medical environments, residential homes, commercial buildings, and businesses. It has been approved for use against some of the most deadly pathogens including: Gram-positive bacteria, such as Staphylococcus aureus (presently considered to be the most deadly bacteria in U.S. hospitals), Gram-negative bacteria, such as Salmonella choleraesuis (responsible for food poisoning), and nosocomial or hospital-acquired pathogens, such as Pseudomonas aeruginosa (often found in burns and cuts). Silver compositions of the present invention can be sprayed in and around occupied areas without endangering the lives of people. One can disinfect surfaces selected from the group consisting of walls, tables, chairs, light fixtures, bathrooms, glass, porcelain, metal, glazed ceramic, enameled and painted by means of spraying or by means of wiping with a silver composition of the present invention. A preferred method of disinfecting comprises one or more of the steps of cleaning the surface to be disinfected, applying, by means of a spray, mop, sponge, or cloth, a composition of the present invention, thoroughly wetting the area to be disinfected, allowing the surface to remain wet for at least 10 minutes at a temperature of at least 20.degree. C. (time/temperature interrelation can be adjusted via the Arrhenius equation or other means known to one of ordinary skill), and wiping the surface with a clean paper or cloth towel. Compositions for disinfecting surfaces comprise those comprising 5 to 40 ppm silver. A preferred composition of the present invention for disinfecting surfaces comprises (32.+-.3) ppm silver. Another preferred composition of the present invention for disinfecting surfaces comprises (10.+-.2) ppm silver. Another preferred composition of the present invention for disinfecting surfaces comprises (22.+-.2) ppm silver. 14. Evidence of Efficacy of Silver Composition as Super Disinfectant A. Purpose of Example The purpose of this example is to show the antimicrobial activity of a silver composition of the present invention (here 10 ppm silver, 14 ppm silver with 1.5 wght % hydrogen peroxide, and 32 ppm silver) against the test organism Yersinia pestis, the etiologic agent of bubonic plague. By performing a standard kill-time assay using a Y. pestis suspension, it is demonstrated that silver compositions of the present invention are effective even against the bubonic plague bacteria. B. Material and Methods Y. Pestis, strain D27, was grown on a Columbia Agar plate for about 24 hours at 30.degree. C. in a 5% CO.sub.2 incubator. Growth from the plate was scraped into suspension, using 3 ml of sterile HPLC water. The suspension was transferred to a 50 ml conical centrifuge tube. The plate was then rinsed using an additional 2 ml of HPLC water. This rinse was added to the centrifuge tube. The tube was centrifuged at 3,500.times.g for 5 minutes. The supernatant was discarded and the pellet was resuspended in 1 ml of HPLC water, to give a final concentration of approximately 10.sup.10 cells per ml. The method involved the following steps: 1 A 9.9 ml aliquot of the silver composition to be tested was placed in a sterile 20 mm.times.150 mm tube. The tube was equilibrated in a 20.degree. C. water bath. 2 The tube of silver composition was inoculated with 100 .mu.l of the test organism suspension at time zero to form a mixture. The tube was immediately vortexed and returned to the water bath. 3 At 2 min, 3 min, 4 min, and 5 min for 10 ppm or 32 ppm silver or 2 min, 4 min, 6 min and 8 min for 14 ppm silver with 1.5% v/v H.sub.2O.sub.2, 1 ml of organism/silver mixture was removed to 99 ml of neutralizer in a 250 ml Erlenmeyer flask. The flask was mixed thoroughly. 4 The neutralized suspension was immediately serially diluted 1:10 in physiological saline solution (PSS). 5 The number of viable organisms in selected dilution tubes and flasks was assayed by membrane filtration. One ml aliquots were plated in duplicate. The membranes were washed with about 150 ml (or 250 ml if the sample was taken from the neutralizer flask) of sterile phosphate buffered saline and removed to Columbia Agar plates. The entire remaining contents (98 ml) of the 4 & 5 min neutralizer flasks were also plated. The plates were incubated at 30.degree. C. in a 5% CO.sub.2 incubator for 72 hours. 6 The number of colonies on each filter was counted and log reductions were computed. C. Results The results for 10 ppm silver are as follows: TABLE-US-00018 Time Log Reduction Percent Kill 2 min 2.63 99.77 4 min 3.20 99.94 6 min 3.46 99.97 8 min 3.68 99.98 The calculated regression equation for these data is Y=2.3965+0.1696 x. This indicates that the time for a 6-log reduction is 21.2 minute. The results for 32 ppm silver are as follows: TABLE-US-00019 Time Log Reduction Percent Kill 2 min >7.61 99.999998 4 min >7.61 99.999998 6 min >7.61 99.999998 8 min >7.61 99.999998

The results for 14 ppm silver with 1.5% v/v H.sub.2O.sub.2 are as follows:

TABLE-US-00020 Time Log Reduction Percent Kill 2 min 3.27 99.95 3 min 4.72 99.998 4 min 5.36 99.9996 5 min 6.47 99.99997

The calculated regression equation for these data is Y=1.371+1.024 x. This indicates that the time for a 6-log reduction is 4.52 minute.

The silver composition of the present invention exhibited significant bactericidal activity against Y. pestis, the etiologic agent of bubonic plague. The 32 ppm composition gave more than a 7 log reduction (essentially total kill) in less than 2 min. The data show that the 10 ppm silver takes some 20 min to achieve a 6 log kill. The silver and hydrogen peroxide show significant synergism with a calculated 6 log kill of under 5 min. This is much better than 10 ppm silver alone. The level of 14 ppm silver was chosen because the data of other experiments suggested that this level of silver combined with hydrogen peroxide would achieve results approaching those of the 32 ppm silver product.

15. Data Summary

The following table contains a summary of the above results in terms of the effects of the inventive silver composition on a wide variety of microbes and human diseases. In some cases, the data presented in the table is not repeated above. However, the results were obtained using the procedures explained above so that one of ordinary skill in the art can readily replicated the results.

Human Diseases Cured By and Pathogens Killed by the Inventive Silver Composition:

TABLE-US-00021 Disease Pathogen Effective Concentration Boils Staphylococcus aureus Killed @ 5 ppm Osteomyelitis Staphylococcus aureus Killed @ 5 ppm Bacillary Dysentery Shigella boydii Killed @ 2.5 ppm Burn Infections Pseudomonas aeruginosa Killed @ 5 ppm Dental Plaque Streptococcus mutans Killed @ 5 ppm Diarrhea (Bloody) Shigella boydii Killed @ 2.5 ppm Diarrhea Escherichia coli Killed @ 2.5 ppm Ear Infection Haemophilus influenzae Killed @ 1.25 ppm Ear Infection Streptococcus pneumonie Killed @ 2.5 ppm Enteric Fever Salmonella tyhimurium Killed @ 2.5 ppm Epiglottitis (In children) Haemophilus influenzae Killed @ 1.25 ppm Eye Infections Staphylococcus aureus Killed @ 5 ppm Corneal Ulcers-Keratitis Pseudomonas aeruginosa Killed @ 5 ppm Food Poisoning Salmonella arizona Killed @ 5 ppm Food Poisoning Salmonella tyhimurium Killed @ 2.5 ppm Food Poisoning Escherichia coli Killed @ 2.5 ppm Endocarditis Streptococcus faecalis Killed @ 2.5 ppm Endocarditis Streptococcus gordonii Killed @ 5 ppm Meningitis Haemophilus influenzae Killed @ 1.25 ppm Meningitis Enterobacter aerogenes Killed @ 2.5 ppm Meningitis Pseudomonas aeruginosa Killed @ 5 ppm Meningitis Streptococcus pneumonie Killed @ 2.5 ppm Nosocomial Infections Klebsiella pneumoniae Killed @ 2.5 ppm Nosocomial Infections Pseudomonas aeruginosa Killed @ 5 ppm Nosocomial Infections (From Streptococcus pyogenes Killed @ 1.25 ppm hospitals) Pneumonia Staphylococcus aureus Killed @ 5 ppm Pneumonia Haemophilus influenzae Killed @ 1.25 ppm Pneumonia Pseudomonas aeruginosa Killed @ 5 ppm Pneumonia Streptococcus pneumonie Killed @ 2.5 ppm Respiratory Tract Infections Streptococcus pyogenes Killed @ 1.25 ppm Respiratory Tract Infections E. coli Killed @ 2.5 ppm,, Respiratory Tract Infections Klebsiella pneumoniae Killed @ 2.5 ppm Scarlet Fever Streptococcus pyogenes Killed @ 1.25 ppm Septicemia Enterobacter aerpyogenes Killed @ 2.5 ppm Sinus Infections Haemophilus influenzae Killed @ 1.25 ppm Sinusitis Streptococcus pneumonie Killed @ 2.5 ppm Impetigo Staphylococcus aureus Killed @ 1.25 ppm Skin Infections Staphylococcus aureus Killed @ 5 ppm Skin Infections Streptococcus pyogenes Killed @ 1.25 ppm Strep Throat Streptococcus pyogenes Killed @ 1.25 ppm Suppurative Arthritis Haemophilus influenzae Killed @ 1.25 ppm Throat Infections Haemophilus influenzae Killed @ 1.25 ppm Tooth Decay Streptococcus mutans Killed @ 5 ppm Urethritis (Men) Trichomonas vaginalis Killed @ 10 ppm Urinary Tract Infections E. coli Killed @ 2.5 ppm Urinary Tract Infections Klebsiella pneumoniae Killed @ 2.5 ppm Urinary Tract Infections Pseudomonas aeruginosa Killed @ 5 ppm Urinary Tract Infections Streptococcus faecalis Killed @ 2.5 ppm Urinary Tract Infections Enterobacter aerpyogenes Killed @ 2.5 ppm Vaginitis (Women) Trichomonas vaginalis Killed @ 10 ppm Wound Infections Escherichia coli Killed @ 2.5 ppm Wound Infections Enterobacter aerpyogenes Killed @ 2.5 ppm Wound Infections Klebsiella pneumoniae Killed @ 2.5 ppm Wound Infections Pseudomonas aeruginosa Killed @ 5 ppm Wound Infections Streptococcus faecalis Killed @ 2.5 ppm Yeast Infections Candida albicans Killed @ 10 ppm

The following claims are thus to be understood to include what is specifically illustrated and described above, what is conceptually equivalent, what can be obviously substituted and also what essentially incorporates the essential idea of the invention. Those skilled in the art will appreciate that various adaptations and modifications of the just-described preferred embodiment can be configured without departing from the scope of the invention. The illustrated embodiment has been set forth only for the purposes of example and that should not be taken as limiting the invention. Therefore, it is to be understood that, within the scope of the appended claims, the invention may be practiced other than as specifically described herein.

* * * * *
[Image]
[View Shopping Cart] [Add to Shopping Cart]
[Top]
[Home] [Boolean Search] [Manual Search] [Number Search] [Help]
 

1. Project Name

Cure Aids Now

CURE AIDS NOW

2. Project Location

Cure Aids Now CURE AIDS NOW is non -profit organizational plan to establish Global Headquarters to be intialized under a charitable endowment in San Francisco, Beverly Hills, New York and Miami Beach.

San Francisco will be headquarters for North America. Operational centers will be positioned globally under endowment.

The unique requirements and non-profit organizations of an HIV/AIDS eradication program for each specific country will be developed according to US and International By Laws amid world challenging conditions of poverty and disaster relief in terms of the pandemic “cure” of HIV/AIDS.

Current T.E.D. mapped Geographical pandemic HIV/AIDS strains are a prioritization for an eradication program in India, Africa, South America with a pilot program for Haiti.

U.S. Cities Prioritized HIV/AIDS Clinical Trials is phase II with organized eradication plans for the future research for an anti – viral cure that identifies the hiding place of HIV in the Human Blood and lymph tissues:

Miami / San Francisco / New York City &  The CURE AIDS NOW ERADICATION PLAN will seek to raise AWARENESS for an immediate need for HIV/AIDS Epicenters in the USA.

THE MISSION STATEMENT AND SIGNIFICANT PURPOSE OF CURE AIDS NOW FOUNDATION is to raise AWARENESS of an immediate pandemic need for an HIV/AIDS eradication plan that supports research for an end to HIV/AIDS.

CURE AIDS NOW will partner with RED FOUNDATION and ONE FOUNDATION in Washington D.C.

THE U.S. POPULATION MAY NOW POSSIBLY BE HIV/AIDS INFECTED WITH HIV HIDING IN UNTESTED US CITIZENS.
ACCORDING TO THE CENTER FOR DISEASE CONTROL.

ANYTHING OTHER THAN A U.S.A. LED GLOBAL PHILANTHROPIC HIV/AIDS ERADICATION EFFORT WITH AN INTERNET TECHNOLOGY SOLUTION AND GLOBAL PARTNER IS INSANITY AT THIS POINT IN HISTORY!

3. Sponsor Coordinates

Philanthropy Bankers : JP Morgan Philanthropy

CURE AIDS NOW will institute A Non – Profit Family Foundation Program to Brand HIV/AIDS eradication donors and partners will be instituted with an endowment.

Mentor Program :  Bill & Melinda Gates Foundation / Polo Eradication

Fax: 510 733 9211

Email: thecure@cureaidsnow.com

Website: cureaidsnow.com

  1. CURE AIDS NOW US Taxpayer/Employer ID Number #47 -4521572
  2. *non-profit organization

CURE AIDS NOW is a NON – PROFIT HIV / AIDS GLOBAL ERADICATION PLAN to benefit HIV/AIDS ERADICATION AWARENESS. CURE AIDS NOW is a non profit awareness and research plan that will seek an endowment and honorarium to institute a GLOBAL HIV AIDS ERADICATION program with an Internet Technology partner.

San Francisco is home to CURE AIDS NOW GLOBAL HIV / AIDS ERADICATION PLAN in conjunction with the plans for a non – profit research endowment inclusive of a non- profit structure with an incumbent plan for a charitable partnership of bio-pharmeceutical anti-virus and anti-retro-virus therapies.

CURE AIDS NOW has a NON – PROFIT plan for strategic partnership with Google.org and Adwords Campaign for the non – profit endowment and funding commitment.

CURE AIDS NOW

CURE AIDS NOW HIV/AIDS NON – PROFIT ERADICATION PLAN/strong>

5. Financial Information

1) Project Duration: [Long term] in perpetuity.

2) Development Capitalization Goal: Sustainable Endowment

 3)* CURE AIDS NOW is a non-profit HIV/AIDS eradication ; the ONLY HIV / AIDS ERADICATION PLAN EVER PUBLISHED BY AN ORGANIZATION OR INDIVIDUALplan

* Inclusive of facilities, infrastructure, cutting edge equipment, staff & R&D

CURE AIDS NOW will raise AWARENESS for a non-profit HIV / AIDS Eradication GOLBAL PLAN and become sustainable with a $5M annual operational budget. ST YEAR ANNUAL BUDGET

* CURE AIDS NOW Initial Project Endowment Allocation Goal $50 Million US Dollars.

* CURE AIDS NOW has put a non-profit price on global eradication of HIV/ AIDS Longterm Goal $50 Billion US Dollars GLOBAL PEACE BOND

THE PRICE OF A GLOBAL PEACE BOND HIV/ AIDS ERADICATION CURE -$50 BILLION TOTAL – HIV/AIDS ERADICATION + WORLD PEACE BOND – CURE AIDS NOW HAS PUT A NON-PROFIT PRICE ON ERADICATING HIV / AIDS GLOBALLY WITH AN INTERNET TECHNOLOGY SOLUTION

6. Project Overview & Project Description

CURE AIDS NOW CURE AIDS NOW WILL RAISE AWARENESS of the Immediate need of a non-profit plan to end the pandemic and THE URGENT NEED TO CONDUCT CLINICAL TRIALS TO RESEARCH AN ANTIVIRAL FOR HIV/AIDS.

CURE AIDS NOW CURE AIDS NOW WILL RAISE THE AWARENESS FOR A STUDY CONSISTING OF ANTIVIRAL CLINICAL TRIALS AND GENETIC ENCODING TO MAP HIV/AIDS FOR ERADICATION OF THE INFECTION IN THE HUMAN BLOOD AND IN THE HUMAN GENOME.

CURE AIDS NOW HAS A NON – PROFIT PLAN TO ERADICATE HIV / AIDS FROM THE HUMAN GENOME BY RAISING AWARENESS FOR THE NEED OF CLINICAL TRIALS WILL BE CONDUCTED IN ASSOCIATION WITH

AIDS RESEARCH ALLIANCE IN SOUTHERN, CALIFORNIA.

PROJECT MISSION STATEMENT

CURE AIDS NOW WILL PLAN NON PROFIT CELEBRITY CURE AIDS NOW CONCERTS AND EVENTS WITH DIGITAL DOWNLOADS OF ARTIST CONTRIBUTED MUSIC AND FURTHER RAISE AWARENESS TO SUPPORT AN INTERNET TECHNOLOGY SOLUTION THROUGH A WORLDWIDE HIV / AIDS ERADICATION BOND OF $50 BILLION US DOLLARS.

(CAN) CURE AIDS NOW HAS DESIGNED AN HIV/AIDS ERATICATION PROGRAM TO PARTNER WITH GOOGLE.ORG ENSURING ERADICATION COMMUNITIES WITH GOOGLE MEDICAL SUPPORT INCLUDING ONLINE MEDICAL RECORDS WITH A ONLINE CELL PHONE DEVICE FOR VERIFYING AND ASSISTING EVERY HIV / AIDS INFECTED PARTICIPANT IN THE WORLD.

(CAN) CURE AIDS NOW NON – PROFIT HIV /AIDS ERADICATION PLAN ENVISIONS A META-MOMENT IN THE FUTURE OF CYBERSPACE AND HUMAN HISTORY WHERIN AN I.T. SOLUTION FOR ERADICATING THE HIV/AIDS PANDEMIC BECOMES POSSIBLE WITH A T.E.D. SUPPORTED GOOGLE MONITORING TRACKING SYSTEM TO MANAGE AND PROVE RESULTS TO PHILANTHROPY NON – PROFIT PARTICIPANTS .

AN INTERNET TECHNOLOGY SOLUTION FOR HIV/AIDS

TODAY, CURE AIDS NOW INTEGRATES AN I.T. SOLUTION PROVIDER FOR GLOBAL HIV/AIDS ERADICATION THAT CREATES SOLAR POWERED THIRD WORLD INTERNET DWELLINGS AS BUILDING BLOCKS IN HIV/AIDS ERADICATION COMMUNITIES.

IS A NETWORKED BUILDING BLOCK IN FUTURE I.T. COMMUNITIES CREATING A LOW-IMPEDENCE INTERNET READY COMMUNITY FOR A FUTURE GLOBAL MEDICAL SATELLITE INTERNET EXPLOSIVE GROWTH TO SUPPORT HIV AIDS ERADICATION IN DEVELOPING COUNTRIES & CURE AIDS NOW HAS AN HIV / AIDS ERADICATION PLAN PARTNERING A NON – PROFIT GOOGLE MEDICAL HIV/AIDS ERADICATION FRONT PAGE.

CURE AIDS NOW HAS A PLAN FOR EACH DWELLING AND PATENTED SMARTBLOCK SATELLITE INTERNET GOOGLE LINK COMPUTER HOME TO RETURNS GOOGLE NON – PROFIT MEDICAL ADVERTISING REVENUE WITH A GOOGLE TRACKED MICRO-FINANCE SYSTEM FOR USERS TO RUN AN ERADICATION CENTER FOR ANY PANDEMIC.

CURE AIDS NOW GLOBAL HIV /AIDS ERADICATION PLAN IS DESIGNED AS A GOOGLE PARTNERED HIV/AIDS ERADICATION PROGRAM

CURE AIDS NOW IS A CHARITABLE ORGANIZATIONAL PLAN PARTNERED WITH PHILANTHROPIC AND SOCIAL ENTREPENEUR APPLICATIONS

OUR MISSION STATEMENT IS TO CREATE AWARENESS FOR THE IMMEDIATE NEED OF AN HIV / AIDS GLOBAL ERADICATION PLAN FOR A PARTNERED GOOGLE POWERED HIV/AIDS ERADICATION PROGRAM WITH CONNECTIVITY TO THE INTERNET FOR MEDICAL RECORDS ONLINE OF ALL HIV/AIDS PATIENTS IN THE WORLD

CURE AIDS NOW HAS A PLAN TO END THE PANDEMIC – COUNTING DOWN TO A GLOBAL META-MOMENT WHEN WE CAN CURE AIDS NOW AND ERADICATE THE PANDENIC FROM THE HUMAN GENOMIC CULTURE.

MANIFEST DESTINY OF HIV/AIDS ERADICATION

(CAN) CURE AIDS NOW will fund clinical trials of an HIV/AIDS NON-TOXIC ANTIVIRAL.

A GRANT award will be bestowed on the winning patent of a nontoxic HIV/AIDS antiviral biopharmaceutical.

(CAN) Cure Aids Now Foundation is a Non-Government Organization (NGO)

CAN Foundation is uniquely orchestrated to transcend borders and barriers for the implementation of humanitarian efforts for HIV/AIDS genetic tracking & eradication programs around the world.

CURE AIDS NOW “LIVE AID” “LIVE EARTH” ON NETWORK SIMULCAST

To support global awareness a web site dedicated to a music & media approach to charitable contributions will be blended with website downloads of select songs and videos of celebrities.

CURE AIDS NOW will be the charitable organization of this monumental Global “LIVE AID” or “LIVE EARTH” type event with simulcasts on network television.

CLINICAL TRIAL DNA AND GENOME TRACKING OF HIV/AIDS

CURE AIDS NOW Foundation will fund clinical trials for a non-toxic antiviral with two criteria in reporting results in DNA & Genome tracking. A key element of the Cure Aids Now Foundation will be its ability to bring existing humanitarian groups together with celebrity spokespersons and media participants.

CURE AIDS NOW PURPOSE

(CAN) CURE AIDS NOW Foundation exists for the purpose of coordinating resources to provide for media support of H.I.V./AIDS eradication communities & the charitable development of HIV/AIDS eradication programs.

CURE AIDS NOW GLOBAL ERADICATION META-MOMENT

(CAN) CURE AIDS NOW FOUNDATION plans a global eradication program partnered with Google to create specialized internet ready housing and a Google front page for free online medical records for the basic needs of third world children, mothers & families infected with HIV/AIDS towards a global eradication meta-moment.

The Cure Aids Now Foundation will impact our world while funding the only clinical trial effective HIV/AIDS antiviral eradication program in existence.

(CAN) CURE AIDS NOW FOUNDATION will Improve the quality of life on planet earth for third-world children on a localized level through DEVELOPING A CHILD NEBULIZER HIV/AIDS ERADICATION PROGRAM & funding childcare clinical trials and the charitable research and development of an HIV/AIDS antiviral especially for children.

(CAN) CURE AIDS NOW FOUNDATION plans a partnership with Google.org to Institute HIV/AIDS eradication education online with relevant information resources on an HIV/AIDS clinical trial sponsored eradication medical front page with micro-finance portal.

(CAN) CURE AIDS NOW FOUNDATION plans a partnership with Google advertising support of Global microfinance, Global Satellite and Global Educational support through a third world solar powered internet Google medical homepage in every language on the face of the earth.

(CAN) Cure Aids Now Foundation

Humanitarian efforts foresee a  third world, low impedance, solar powered Computer Home ready built for Internet Advertisement revenue to support HIV/AIDS eradication education, microfinance & free online medical records;

Can Foundation partners Free Google Meta- Moment micro-finance accounts.

b) Return to individuals and nations the liberty to dream and live one’s dream

c) Enhance self-esteem and inspire confidence among the children of the world

d) Create exciting charity opportunities for young adults on a global basis

(CAN) CURE AIDS NOW FOUNDATION DEVELOPS CLINICAL TRIAL FOR HIV IMMUNE BOOSTERS AND VIRAL SUPPRESSANT ANTIOXIDANTS

In order to mobilize the abilities in third-world countries to join Cure Aids Now Foundation we will provide an immediate way for them to contribute to the survival of their families through research of a deliverable non-toxic HIV/AIDS immune booster & viral suppressants & antiviral anti-oxidants.

(CAN) Cure Aids Now Microfinance & Internet Ready HIV/AIDS Housing

Cure Aids Now will research and develop eradication programs; microfinance and Internet ready communal housing and hydroponics agriculture, online medical records and micro loans for very small eradication sponsored businesses helping countries India & Africa break the cycle of illness/poverty/pandemic.

(CAN) AND MULTILINGUAL KEYBOARD SOFTWARE PARTNERED WITH YALE & GOOGLE. ORG.

Another emphasis will be on developing technologies on a multilingual easy-to-learn software basis as we establish remote eradication communities developed at Yale with research and learning centers suitable for reaching the poor at a grass-roots level, ultimately bringing all HIV/AIDS infected children of the world into the 21st century as global citizens.

(CAN) AND GENERIC PHARMA R&D IN INDIA

Ongoing research and development of nontoxic antiviral patented pharmacy products will be researched concurrently with clinical trials to discover immune boosting homeopathic and herbal therapies conformed to protein markers with ionic pathway & proven medical efficacy.

(CAN) AND R&D PARTNERSHIPS WITH CIPLA & AURIBINDO PHARMA

Through research and development in concurrence with clinical trials and genetic encoding we can fulfill protocols to increase effectiveness of anti-viral and immune boosting treatments while producing patents at generic price points for third world countries like Africa, India, Mexico South America and the Caribbean, particularly Haiti.

CURE AIDS NOW

Charitable Foundation

(CAN) Cure Aids Now Foundation will fund research and development of technologies including hand-held nebulizer devices currently in development, which will be given to those unable to afford fundamental medical care.

An example of cutting-edge technology developed by the Cure Aids Now foundation is a CELLPHONE / NEBULIZER delivery system for a recently FDA & EPA approved and developed HIV/AIDS patented antiviral therapy of aqueous SILVER SOL and MARINE PLASMA viral protein DNA markers.

Coupled with state–of–the-art eradication education software, Internet ready housing modules, modeled after the copyrighted smart block Internet housing community with Solar Powered Battery Storage and medical computer housing. Cure Aids Now is the most sophisticated solution provider to raise awareness for the only HIV/AIDS eradication plan in existence.

(CAN) Cure aids Now Foundation has instituted an HIV/AIDS methodology, which is being tailored to raise awareness of an anti – viral protocol and internet technology solution provider and boost the immune system of infected HIV + AIDS victims so the disease can be eradicated in communities to instill self-esteem and inspire confidence in the third-world for an Internet Technology Solution.

7. Organizations and Experience/ Expertise

 Mission Statement - Cure Aids Now Foundation, mission is to positively and noticeably impact our world for peace, love and compassionate consciousness including awareness toward social activism and corporate mindfulness encompassing philanthropy &compassion in a community effort of HIV/AIDS eradication on a global scale.

 Cure Aid Now Foundation *SmartBlock Technology - patent pending

Smart Block TM : The construction industry breakthrough of an extruded concrete poured building block and invention of The Computer Home –  inclusive of a microchip onboard computer innovation to facilitate a computer housing unit with a third world solar powered internet and Google Medical Page operating system powered by a patent pending medical cellphone / nebulizer / camera device for uploading verified medical data and records.

The Computer Home is a patent-pending system design for onboard-computer housing for a third world computer housed dwelling. A Google medical display and low impedance operating system access solar powered battery storage for a satellite global medical internet eradication and verification network. Each 200sq. ft. smart house is an I.T. solution provider for HIV/AIDS eradication with onboard google medical homepage and is waterproof, fireproof and will withstand winds of 200 mph at a cost of a laptop.

CURE AIDS NOW

Charitable Foundation

Mr. Bronzino is responsible for founding Cure Aids Now and for linking the possible convergence of the Cure Aids Now and Brevity APPLE INC. & AMFAR charitable fundraising campaigns in an alliance with the HIV – AIDS eradication effort and proposed HIV/AIDS platform policy.

(CAN) founder Mr. Bronzino met at the Atlantic headquarters for Cure Aids Now with Mr. Al Wichtoski, managing director of ABDATA LTD., in order to bring the Cure Aids Now campaign issue to the internet fund raising platform.

Mr. Bronzino & Mr. Al Wichtoski who has been selected as data manager and the campaign fundraising managing director. CURE AIDS NOW is an idea who’s time for funding has definitely come from necessity as we are combatting a new wave of HIV AIDS infection in the urban centers of the USA.

ABDATA LTD. and Mr. Wichtoski are our choice for data fundraising with a major Internet Technology Company and Patented CURE AIDS NOW SILVER SOL TECHNOLGY.

Mr. Wichoski after meeting CAN Foundation agreed the time has come for the Cure Aids Now effort to reach a national platform through an association with AMFAR as a contributor. ABDATA LTD. and Mr. Wichoski are also the fundraisers for over $130 Million for AMFAR.

Can Foundation will institute a peace bond capital plan for facilitating funding of a ;

YES WE CAN RAISE AWARENESS FOR THE NEED OF A GLOBAL HIV AIDS ERADICATION PLAN AND CURE AIDS NOW PEACE BOND OF $50 Billion US Dollars.

Together our voice is the…

 CURE AIDS NOW FOUNDATION

“We are the Champions of the world.”

-Queen

CURE AIDS NOW

Charitable Foundation

Cure Aids Now through charitable contributions delivers the message of a unified vision.

Cure Aids Now was founded to create positive world community activism through a global musical event
CURE AIDS NOW “LIVE” that will be produced to reach an audience on a larger scale than LIVE AID with a new vision to stem the HIV/AIDS pandemic.

Cure Aids Now (CAN) Foundation was formed to mobilize the power of love and music in the media world towards immediate charitable funding of research and development of a non-toxic antiviral cure for HIV/AIDS.

Cure Aids Now will also benefit research grants and funding of double blind clinical trials for a non-toxic antiviral HIV/AIDS eradication protocol.

Yes We CAN… award a grant to every clinical trial that produces and publishes a non-toxic holistic antiviral HIV/AIDS medical breakthrough success under scientific survey in association with a U.S. University.

Yes We CAN… with charitable contributions research and develop a feasible HIV/AIDS epidemic eradication program to stem the pandemic.

Yes We CAN… research a cure for HIV/AIDS to end the spread of the pandemic new killer strains of the disease.

Yes We CAN… research and develop a plan for a feasible global third world HIV/AIDS eradication program along with an antiviral cure for the HIV/AIDS virus.

Yes We CAN… give hope & dignity to impoverished and often-homeless HIV/AIDS infected people and especially children all over the world and in high risk third world countries with a focus on India & Africa, Latin America, Haiti and the West Indies.

Yes We CAN… through charitable contributions begin funding clinical trials to research and develop a successful HIV/AIDS cure now.

Cure Aids Now Foundation is an ideal whose time is here and now. As one voice, together, we can bring about a unified vision for change in political policy and the world’s awareness toward a unified cause of charitable global social activism in an effort to research and develop a cure for HIV/AIDS.

“I tried to laugh about it… cover it all up with lies

…hiding the tears in my eyes”

-The Cure

CURE AIDS NOW

Charitable Foundation

Yes We CAN … fund charitable clinical trials and through philanthropic donations research and develop and publish breakthrough patents for holistic non-toxic HIV/AIDS antiviral and patentable peptide delivery and time-release systems.

Yes WE CAN…partner with other foundations, AMFAR, The Material World Trust, Band Aid Trust and the Elton John, Magic Johnson and Elizabeth Taylor AIDS Foundations.

Yes We CAN… create a global telethon musical event larger in scale than LIVE AID to raise awareness and charitable contributions throughout historic musical performances.

Yes We CAN… research the rainforests of the world for new botanical breakthrough developments of non-toxic biopharmaceutical & nutraceutical HIV/AIDS antiviral curatives.

Yes We CAN…research SILVER SOL nanotechnology and IMPREX process biopharmaceutical and nutraceutical patented processes to discover anti-viral protocols with patented delivery systems and partner with Big Pharma companies.

Yes We CAN… research and develop patented time released anti-viral capsules, topical infusion crèmes, Bio-pharmaceutical clay patches and vacuum sealed glass ampoule nebulizer delivered eradication protocols for maximum HIV/AIDS anti-viral effect and efficacy.

Yes We CAN… fund the research and development of the ultimate eradication anti-viral for HIV/AIDS through new clinical trials and grants.

Yes We CAN… award a grant to each and every breakthrough medical publication of a proven process or medically published anti-viral cure under scientific double-blind study.

Yes We CAN… unite in One voice and One dream envisioning a worldwide effort to

Eradicate the HIV/AIDS virus beginning with a “LIVE” Global Musical Telethon to fund a charitable series of clinical trials with an intent for a discovery of a patentable anti-viral to CURE AIDS NOW “LIVE”.

Blackbird singing in the dead of night takes these broken wings and learns to fly.

You are only waiting for this moment to arrive -The Beatles

CURE AIDS NOW

Charitable Foundation

“I look at you all see the love there that’s sleeping”

-George Harrison

Cure Aids Now is a NON PROFIT organizational plan integrating a worldwide HIV/AIDS eradication program, which includes a mass anti-viral inoculation. Through charitable contributions we support the philanthropic funding of research and development of third-world housing solutions to support HIV/AIDS eradication programs.

Cure Aids Now was founded to raise awareness for the philanthropic research of Internet construction materials containing microchip technology for on-board computer-ready housing, processing a simple solar powered HIV/AIDS eradication operating system in diverse languages. CURE AIDS NOW is poised to create the planning of Internet ready solar powered third-world solution for housing eradication community housing for third world platform and web delivery pandemic eradication system.

Cure Aids Now is a non-profitplan to eradicate HIV AIDS GLOBALLY… with one voice and a united intention.

CURE AIDS NOW

Charitable Foundation

Cure Aids Now … is an NON PROFIT intention with One voice, our intention is to give hope and dignity to the world’s HIV/AIDS infected children and adults through a feasible HIV/ AIDS global eradication plan for homeless masses incorporating HIV/AIDS eradication programs, online medical records and solar powered housing and free internet support in third world countries.

Cure Aids Now has a plan for solar powered third world Internet ready housing which include in-wall computer screen displays for online medical records and Internet ready township networks for community commerce with access to a Google ERADICATION PAGE.

Cure Aids Now will plan each 200 sq. ft. Internet computer on-board solar powered house to be equipped with a simple medical google diagnostic operating system with micro loan access and educational, advertising & trading incomes to provide the software and technical resources to help make third world dreams a reality.

Yes We Can… in essence create awareness to research & development of a brave new world challenging a cure for HIV/AIDS through charitable contributions and a unified vision with compassion to create one voice…with one miracle intention CURE AIDS NOW.

Cure Aids Now with the help of NON PROFIT resources through funding of research and development of HIV/AIDS eradication & economic plans which will include micro loans, day/night housing and third-world online medical & health report records.

“The gears of poverty, ignorance, hopelessness, and low self-esteem create a perpetual failure machine that grinds down dreams from generation to generation. We all bear the cost of keeping it running.”

-Carl Sagan, Astronomer

CURE AIDS NOW

Charitable Foundation

Cure Aids Now … has instituted a plan for the development of patented CURE AIDS NOW anti viral to eradicate the pandemic.

.

Yes We CAN… with your contributions fund research and development of computer onboard solar powered third world community housing with in-wall Internet medical networks and HIV/AIDS eradication software.

Yes We CAN… meet medical & funding demands for care and education and create eco-friendly eradication opportunities with patented internet housing including Internet housing construction systems and new internet ready building blocks and newly invented patent pending IT construction materials.

Cure Aids Now is simply the most comprehensive and feasible patented HIV/AIDS cure and eradication program in existence.

5% of the world population is now possibly HIV Positive.

Any other alternative to a philanthropic HIV/AIDS eradication plan at this point in human history would be prolonging the solution

“Hello… Is there any body out there…?”

-Pink Floyd

CURE AIDS NOW

Charitable Foundation

“Compassion is the cause of omniscience”

-Buddha

OUR HOPE is to help the children of the world infected with HIV/AIDS to regain dignity through the world’s attention and awareness to the cause and research for an HIV/AIDS cure together with funding research for a real and feasible non profit eradication program.

OUR MISSION is to CURE AIDS NOW.

OUR MISSION STATEMENT is to eradicate the HIV/AIDS disease.

OUR GOAL is to fund a breakthrough in bio-pharmaceuticals that will eradicate HIV/AIDS non-toxically from the human genome and DNA.

OUR DREAM is to bring the world community together in love and music on a day worldwide to celebrate a commitment to the global charitable purpose and contribution to CURE AIDS NOW through research and development of a plan to eradicate the HIV/AIDS pandemic.

YES WE CAN and with your help we will research and develop a real eradication program and bring the compassion of the world community to the awareness of OUR mission to CURE AIDS NOW, adding human value to those lives of adults and children infected with HIV/AIDS.